CN116003397A - Benzo-polycyclic thiazoline amide compound and application thereof - Google Patents
Benzo-polycyclic thiazoline amide compound and application thereof Download PDFInfo
- Publication number
- CN116003397A CN116003397A CN202310294139.0A CN202310294139A CN116003397A CN 116003397 A CN116003397 A CN 116003397A CN 202310294139 A CN202310294139 A CN 202310294139A CN 116003397 A CN116003397 A CN 116003397A
- Authority
- CN
- China
- Prior art keywords
- compound
- substituted
- ring
- unsubstituted
- replaced
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 34
- -1 thiazoline amide compounds Chemical class 0.000 claims abstract description 34
- 230000000694 effects Effects 0.000 claims abstract description 32
- 108010020650 COUP Transcription Factor II Proteins 0.000 claims abstract description 25
- 101000588302 Homo sapiens Nuclear factor erythroid 2-related factor 2 Proteins 0.000 claims abstract description 21
- 102100031701 Nuclear factor erythroid 2-related factor 2 Human genes 0.000 claims abstract description 21
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 11
- 206010060862 Prostate cancer Diseases 0.000 claims abstract description 10
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims abstract description 10
- 125000003118 aryl group Chemical group 0.000 claims abstract description 10
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract description 8
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 8
- 239000001257 hydrogen Substances 0.000 claims abstract description 7
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 6
- 239000001301 oxygen Substances 0.000 claims abstract description 6
- 125000002252 acyl group Chemical group 0.000 claims abstract description 5
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims abstract description 5
- 125000003710 aryl alkyl group Chemical group 0.000 claims abstract description 3
- 102000008523 COUP Transcription Factor II Human genes 0.000 claims abstract 5
- 150000003839 salts Chemical class 0.000 claims description 18
- 201000010099 disease Diseases 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 229910052736 halogen Inorganic materials 0.000 claims description 9
- 150000002367 halogens Chemical class 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 125000000027 (C1-C10) alkoxy group Chemical group 0.000 claims description 8
- 230000002018 overexpression Effects 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 5
- 125000001188 haloalkyl group Chemical group 0.000 claims description 5
- 125000001424 substituent group Chemical group 0.000 claims description 5
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 4
- 229910052805 deuterium Inorganic materials 0.000 claims description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 125000003282 alkyl amino group Chemical group 0.000 claims description 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 2
- 125000000623 heterocyclic group Chemical group 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 238000000034 method Methods 0.000 abstract description 16
- 230000005764 inhibitory process Effects 0.000 abstract description 15
- 230000035755 proliferation Effects 0.000 abstract description 6
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract description 4
- 150000001875 compounds Chemical class 0.000 description 167
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 104
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 65
- 239000007787 solid Substances 0.000 description 63
- 238000005160 1H NMR spectroscopy Methods 0.000 description 43
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 32
- 210000004027 cell Anatomy 0.000 description 22
- 102100028226 COUP transcription factor 2 Human genes 0.000 description 21
- 230000015572 biosynthetic process Effects 0.000 description 20
- 238000003786 synthesis reaction Methods 0.000 description 19
- 238000006243 chemical reaction Methods 0.000 description 17
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 16
- 238000005481 NMR spectroscopy Methods 0.000 description 16
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 14
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 14
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 11
- QARBMVPHQWIHKH-KHWXYDKHSA-N methanesulfonyl chloride Chemical group C[35S](Cl)(=O)=O QARBMVPHQWIHKH-KHWXYDKHSA-N 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 10
- 238000004440 column chromatography Methods 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 9
- 125000005842 heteroatom Chemical group 0.000 description 8
- 239000013612 plasmid Substances 0.000 description 8
- 238000006467 substitution reaction Methods 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 239000012071 phase Substances 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 125000006163 5-membered heteroaryl group Chemical group 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 125000004432 carbon atom Chemical group C* 0.000 description 5
- INQOMBQAUSQDDS-BJUDXGSMSA-N iodomethane Chemical class I[11CH3] INQOMBQAUSQDDS-BJUDXGSMSA-N 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 230000002441 reversible effect Effects 0.000 description 5
- 108090000331 Firefly luciferases Proteins 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 4
- 125000005647 linker group Chemical group 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 125000002947 alkylene group Chemical group 0.000 description 3
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229940125782 compound 2 Drugs 0.000 description 3
- 229940125961 compound 24 Drugs 0.000 description 3
- 229940125898 compound 5 Drugs 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- GPAYUJZHTULNBE-UHFFFAOYSA-N diphenylphosphine Chemical compound C=1C=CC=CC=1PC1=CC=CC=C1 GPAYUJZHTULNBE-UHFFFAOYSA-N 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- KTWOOEGAPBSYNW-UHFFFAOYSA-N ferrocene Chemical compound [Fe+2].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 KTWOOEGAPBSYNW-UHFFFAOYSA-N 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 125000005843 halogen group Chemical group 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 3
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 3
- 238000004020 luminiscence type Methods 0.000 description 3
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- FQMZXMVHHKXGTM-UHFFFAOYSA-N 2-(1-adamantyl)-n-[2-[2-(2-hydroxyethylamino)ethylamino]quinolin-5-yl]acetamide Chemical compound C1C(C2)CC(C3)CC2CC13CC(=O)NC1=CC=CC2=NC(NCCNCCO)=CC=C21 FQMZXMVHHKXGTM-UHFFFAOYSA-N 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical group CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- 108700032225 Antioxidant Response Elements Proteins 0.000 description 2
- 108010065376 COUP Transcription Factor I Proteins 0.000 description 2
- 102100028228 COUP transcription factor 1 Human genes 0.000 description 2
- 101710188750 COUP transcription factor 2 Proteins 0.000 description 2
- 208000005623 Carcinogenesis Diseases 0.000 description 2
- 101000609762 Gallus gallus Ovalbumin Proteins 0.000 description 2
- 108010061414 Hepatocyte Nuclear Factor 1-beta Proteins 0.000 description 2
- 102100022123 Hepatocyte nuclear factor 1-beta Human genes 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- 102000006833 Multifunctional Enzymes Human genes 0.000 description 2
- 108010047290 Multifunctional Enzymes Proteins 0.000 description 2
- 108091008747 NR2F3 Proteins 0.000 description 2
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 2
- 239000012124 Opti-MEM Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 108010052090 Renilla Luciferases Proteins 0.000 description 2
- 108700008625 Reporter Genes Proteins 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 125000005605 benzo group Chemical group 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 2
- 230000036952 cancer formation Effects 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000012761 co-transfection Methods 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- MGNZXYYWBUKAII-UHFFFAOYSA-N cyclohexa-1,3-diene Chemical compound C1CC=CC=C1 MGNZXYYWBUKAII-UHFFFAOYSA-N 0.000 description 2
- ZSWFCLXCOIISFI-UHFFFAOYSA-N cyclopentadiene Chemical compound C1C=CC=C1 ZSWFCLXCOIISFI-UHFFFAOYSA-N 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 125000000842 isoxazolyl group Chemical group 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 102000006255 nuclear receptors Human genes 0.000 description 2
- 108020004017 nuclear receptors Proteins 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- IVDFJHOHABJVEH-UHFFFAOYSA-N pinacol Chemical compound CC(C)(O)C(C)(C)O IVDFJHOHABJVEH-UHFFFAOYSA-N 0.000 description 2
- 238000013326 plasmid cotransfection Methods 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 238000001308 synthesis method Methods 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000012096 transfection reagent Substances 0.000 description 2
- 125000001425 triazolyl group Chemical group 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- ASGMFNBUXDJWJJ-JLCFBVMHSA-N (1R,3R)-3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethylcyclopentane-1-carboxamide Chemical compound BrC1=NN(C2=NC(=NC=C21)N[C@H]1C[C@@](CC1)(C(=O)NC)C)C1=CC=C(C=C1)C=1SC(=NN=1)C ASGMFNBUXDJWJJ-JLCFBVMHSA-N 0.000 description 1
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 1
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 1
- HVSYSQGJZITGQV-CCAGOZQPSA-N (1Z,3Z)-cyclonona-1,3-diene Chemical compound C1CC\C=C/C=C\CC1 HVSYSQGJZITGQV-CCAGOZQPSA-N 0.000 description 1
- ABJSOROVZZKJGI-OCYUSGCXSA-N (1r,2r,4r)-2-(4-bromophenyl)-n-[(4-chlorophenyl)-(2-fluoropyridin-4-yl)methyl]-4-morpholin-4-ylcyclohexane-1-carboxamide Chemical compound C1=NC(F)=CC(C(NC(=O)[C@H]2[C@@H](C[C@@H](CC2)N2CCOCC2)C=2C=CC(Br)=CC=2)C=2C=CC(Cl)=CC=2)=C1 ABJSOROVZZKJGI-OCYUSGCXSA-N 0.000 description 1
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 1
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- IUSARDYWEPUTPN-OZBXUNDUSA-N (2r)-n-[(2s,3r)-4-[[(4s)-6-(2,2-dimethylpropyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclobutane]-4-yl]amino]-3-hydroxy-1-[3-(1,3-thiazol-2-yl)phenyl]butan-2-yl]-2-methoxypropanamide Chemical compound C([C@H](NC(=O)[C@@H](C)OC)[C@H](O)CN[C@@H]1C2=CC(CC(C)(C)C)=CN=C2OC2(CCC2)C1)C(C=1)=CC=CC=1C1=NC=CS1 IUSARDYWEPUTPN-OZBXUNDUSA-N 0.000 description 1
- YJLIKUSWRSEPSM-WGQQHEPDSA-N (2r,3r,4s,5r)-2-[6-amino-8-[(4-phenylphenyl)methylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C=1C=C(C=2C=CC=CC=2)C=CC=1CNC1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O YJLIKUSWRSEPSM-WGQQHEPDSA-N 0.000 description 1
- VIJSPAIQWVPKQZ-BLECARSGSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-4-methylpentanoyl]amino]-4,4-dimethylpentanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O VIJSPAIQWVPKQZ-BLECARSGSA-N 0.000 description 1
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 1
- STBLNCCBQMHSRC-BATDWUPUSA-N (2s)-n-[(3s,4s)-5-acetyl-7-cyano-4-methyl-1-[(2-methylnaphthalen-1-yl)methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)N(C(C)=O)C2=CC(C#N)=CC=C2N1CC1=C(C)C=CC2=CC=CC=C12 STBLNCCBQMHSRC-BATDWUPUSA-N 0.000 description 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 1
- UDQTXCHQKHIQMH-KYGLGHNPSA-N (3ar,5s,6s,7r,7ar)-5-(difluoromethyl)-2-(ethylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(NCC)=N[C@H]2[C@@H]1O[C@H](C(F)F)[C@@H](O)[C@@H]2O UDQTXCHQKHIQMH-KYGLGHNPSA-N 0.000 description 1
- HUWSZNZAROKDRZ-RRLWZMAJSA-N (3r,4r)-3-azaniumyl-5-[[(2s,3r)-1-[(2s)-2,3-dicarboxypyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-5-oxo-4-sulfanylpentane-1-sulfonate Chemical compound OS(=O)(=O)CC[C@@H](N)[C@@H](S)C(=O)N[C@@H]([C@H](C)CC)C(=O)N1CCC(C(O)=O)[C@H]1C(O)=O HUWSZNZAROKDRZ-RRLWZMAJSA-N 0.000 description 1
- MPDDTAJMJCESGV-CTUHWIOQSA-M (3r,5r)-7-[2-(4-fluorophenyl)-5-[methyl-[(1r)-1-phenylethyl]carbamoyl]-4-propan-2-ylpyrazol-3-yl]-3,5-dihydroxyheptanoate Chemical compound C1([C@@H](C)N(C)C(=O)C2=NN(C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C2C(C)C)C=2C=CC(F)=CC=2)=CC=CC=C1 MPDDTAJMJCESGV-CTUHWIOQSA-M 0.000 description 1
- OMBVEVHRIQULKW-DNQXCXABSA-M (3r,5r)-7-[3-(4-fluorophenyl)-8-oxo-7-phenyl-1-propan-2-yl-5,6-dihydro-4h-pyrrolo[2,3-c]azepin-2-yl]-3,5-dihydroxyheptanoate Chemical compound O=C1C=2N(C(C)C)C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C(C=3C=CC(F)=CC=3)C=2CCCN1C1=CC=CC=C1 OMBVEVHRIQULKW-DNQXCXABSA-M 0.000 description 1
- YQOLEILXOBUDMU-KRWDZBQOSA-N (4R)-5-[(6-bromo-3-methyl-2-pyrrolidin-1-ylquinoline-4-carbonyl)amino]-4-(2-chlorophenyl)pentanoic acid Chemical compound CC1=C(C2=C(C=CC(=C2)Br)N=C1N3CCCC3)C(=O)NC[C@H](CCC(=O)O)C4=CC=CC=C4Cl YQOLEILXOBUDMU-KRWDZBQOSA-N 0.000 description 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 1
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- GWYPDXLJACEENP-UHFFFAOYSA-N 1,3-cycloheptadiene Chemical compound C1CC=CC=CC1 GWYPDXLJACEENP-UHFFFAOYSA-N 0.000 description 1
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 1
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 1
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 1
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 1
- HZNVUJQVZSTENZ-UHFFFAOYSA-N 2,3-dichloro-5,6-dicyano-1,4-benzoquinone Chemical compound ClC1=C(Cl)C(=O)C(C#N)=C(C#N)C1=O HZNVUJQVZSTENZ-UHFFFAOYSA-N 0.000 description 1
- PYRKKGOKRMZEIT-UHFFFAOYSA-N 2-[6-(2-cyclopropylethoxy)-9-(2-hydroxy-2-methylpropyl)-1h-phenanthro[9,10-d]imidazol-2-yl]-5-fluorobenzene-1,3-dicarbonitrile Chemical compound C1=C2C3=CC(CC(C)(O)C)=CC=C3C=3NC(C=4C(=CC(F)=CC=4C#N)C#N)=NC=3C2=CC=C1OCCC1CC1 PYRKKGOKRMZEIT-UHFFFAOYSA-N 0.000 description 1
- FMKGJQHNYMWDFJ-CVEARBPZSA-N 2-[[4-(2,2-difluoropropoxy)pyrimidin-5-yl]methylamino]-4-[[(1R,4S)-4-hydroxy-3,3-dimethylcyclohexyl]amino]pyrimidine-5-carbonitrile Chemical compound FC(COC1=NC=NC=C1CNC1=NC=C(C(=N1)N[C@H]1CC([C@H](CC1)O)(C)C)C#N)(C)F FMKGJQHNYMWDFJ-CVEARBPZSA-N 0.000 description 1
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 1
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 1
- LFOIDLOIBZFWDO-UHFFFAOYSA-N 2-methoxy-6-[6-methoxy-4-[(3-phenylmethoxyphenyl)methoxy]-1-benzofuran-2-yl]imidazo[2,1-b][1,3,4]thiadiazole Chemical compound N1=C2SC(OC)=NN2C=C1C(OC1=CC(OC)=C2)=CC1=C2OCC(C=1)=CC=CC=1OCC1=CC=CC=C1 LFOIDLOIBZFWDO-UHFFFAOYSA-N 0.000 description 1
- NQLNHTOCFWUYQE-UHFFFAOYSA-N 2-methylpropane-1-sulfonyl chloride Chemical compound CC(C)CS(Cl)(=O)=O NQLNHTOCFWUYQE-UHFFFAOYSA-N 0.000 description 1
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- KDVZADPGGPBAAK-UHFFFAOYSA-N 3-cyano-4-fluorobenzenesulfonyl chloride Chemical group FC1=CC=C(S(Cl)(=O)=O)C=C1C#N KDVZADPGGPBAAK-UHFFFAOYSA-N 0.000 description 1
- APRZHQXAAWPYHS-UHFFFAOYSA-N 4-[5-[3-(carboxymethoxy)phenyl]-3-(4,5-dimethyl-1,3-thiazol-2-yl)tetrazol-3-ium-2-yl]benzenesulfonate Chemical compound S1C(C)=C(C)N=C1[N+]1=NC(C=2C=C(OCC(O)=O)C=CC=2)=NN1C1=CC=C(S([O-])(=O)=O)C=C1 APRZHQXAAWPYHS-UHFFFAOYSA-N 0.000 description 1
- WYFCZWSWFGJODV-MIANJLSGSA-N 4-[[(1s)-2-[(e)-3-[3-chloro-2-fluoro-6-(tetrazol-1-yl)phenyl]prop-2-enoyl]-5-(4-methyl-2-oxopiperazin-1-yl)-3,4-dihydro-1h-isoquinoline-1-carbonyl]amino]benzoic acid Chemical compound O=C1CN(C)CCN1C1=CC=CC2=C1CCN(C(=O)\C=C\C=1C(=CC=C(Cl)C=1F)N1N=NN=C1)[C@@H]2C(=O)NC1=CC=C(C(O)=O)C=C1 WYFCZWSWFGJODV-MIANJLSGSA-N 0.000 description 1
- BFXHJFKKRGVUMU-UHFFFAOYSA-N 4-fluorobenzenesulfonyl chloride Chemical group FC1=CC=C(S(Cl)(=O)=O)C=C1 BFXHJFKKRGVUMU-UHFFFAOYSA-N 0.000 description 1
- HODOSJNSRPXYBH-UHFFFAOYSA-N 5-amino-2,3-dihydroinden-1-one Chemical compound NC1=CC=C2C(=O)CCC2=C1 HODOSJNSRPXYBH-UHFFFAOYSA-N 0.000 description 1
- XFJBGINZIMNZBW-CRAIPNDOSA-N 5-chloro-2-[4-[(1r,2s)-2-[2-(5-methylsulfonylpyridin-2-yl)oxyethyl]cyclopropyl]piperidin-1-yl]pyrimidine Chemical compound N1=CC(S(=O)(=O)C)=CC=C1OCC[C@H]1[C@@H](C2CCN(CC2)C=2N=CC(Cl)=CN=2)C1 XFJBGINZIMNZBW-CRAIPNDOSA-N 0.000 description 1
- WLUVVHKCJKLREB-UHFFFAOYSA-N 7-amino-2,3-dihydrochromen-4-one Chemical compound O=C1CCOC2=CC(N)=CC=C21 WLUVVHKCJKLREB-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- ISMDILRWKSYCOD-GNKBHMEESA-N C(C1=CC=CC=C1)[C@@H]1NC(OCCCCCCCCCCCNC([C@@H](NC(C[C@@H]1O)=O)C(C)C)=O)=O Chemical compound C(C1=CC=CC=C1)[C@@H]1NC(OCCCCCCCCCCCNC([C@@H](NC(C[C@@H]1O)=O)C(C)C)=O)=O ISMDILRWKSYCOD-GNKBHMEESA-N 0.000 description 1
- 125000000041 C6-C10 aryl group Chemical group 0.000 description 1
- KCBAMQOKOLXLOX-BSZYMOERSA-N CC1=C(SC=N1)C2=CC=C(C=C2)[C@H](C)NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)CCCCCCCCCCNCCCONC(=O)C4=C(C(=C(C=C4)F)F)NC5=C(C=C(C=C5)I)F)O Chemical compound CC1=C(SC=N1)C2=CC=C(C=C2)[C@H](C)NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)CCCCCCCCCCNCCCONC(=O)C4=C(C(=C(C=C4)F)F)NC5=C(C=C(C=C5)I)F)O KCBAMQOKOLXLOX-BSZYMOERSA-N 0.000 description 1
- BQXUPNKLZNSUMC-YUQWMIPFSA-N CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 Chemical compound CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 BQXUPNKLZNSUMC-YUQWMIPFSA-N 0.000 description 1
- 102000039542 CNC family Human genes 0.000 description 1
- 108091067346 CNC family Proteins 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 229940126657 Compound 17 Drugs 0.000 description 1
- 229940126639 Compound 33 Drugs 0.000 description 1
- 229940127007 Compound 39 Drugs 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 1
- 101150116862 KEAP1 gene Proteins 0.000 description 1
- 102000004034 Kelch-Like ECH-Associated Protein 1 Human genes 0.000 description 1
- 108090000484 Kelch-Like ECH-Associated Protein 1 Proteins 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 208000004852 Lung Injury Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 1
- 108091008640 NR2F Proteins 0.000 description 1
- 238000003725 ONE-Glo Luciferase Assay System Methods 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 206010069363 Traumatic lung injury Diseases 0.000 description 1
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 1
- SPXSEZMVRJLHQG-XMMPIXPASA-N [(2R)-1-[[4-[(3-phenylmethoxyphenoxy)methyl]phenyl]methyl]pyrrolidin-2-yl]methanol Chemical compound C(C1=CC=CC=C1)OC=1C=C(OCC2=CC=C(CN3[C@H](CCC3)CO)C=C2)C=CC=1 SPXSEZMVRJLHQG-XMMPIXPASA-N 0.000 description 1
- SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical group CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000005210 alkyl ammonium group Chemical group 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000003277 amino group Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000002622 anti-tumorigenesis Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 150000005840 aryl radicals Chemical class 0.000 description 1
- 125000000732 arylene group Chemical group 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- CSKNSYBAZOQPLR-UHFFFAOYSA-N benzenesulfonyl chloride Chemical group ClS(=O)(=O)C1=CC=CC=C1 CSKNSYBAZOQPLR-UHFFFAOYSA-N 0.000 description 1
- 125000006580 bicyclic heterocycloalkyl group Chemical group 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000002737 cell proliferation kit Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 229940126543 compound 14 Drugs 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 229940126142 compound 16 Drugs 0.000 description 1
- 229940125810 compound 20 Drugs 0.000 description 1
- 229940126086 compound 21 Drugs 0.000 description 1
- 229940126208 compound 22 Drugs 0.000 description 1
- 229940125833 compound 23 Drugs 0.000 description 1
- 229940125846 compound 25 Drugs 0.000 description 1
- 229940125851 compound 27 Drugs 0.000 description 1
- 229940127204 compound 29 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125877 compound 31 Drugs 0.000 description 1
- 229940125878 compound 36 Drugs 0.000 description 1
- 229940125807 compound 37 Drugs 0.000 description 1
- 229940127573 compound 38 Drugs 0.000 description 1
- 229940126540 compound 41 Drugs 0.000 description 1
- 229940125936 compound 42 Drugs 0.000 description 1
- 229940125844 compound 46 Drugs 0.000 description 1
- 229940127271 compound 49 Drugs 0.000 description 1
- 229940126545 compound 53 Drugs 0.000 description 1
- 229940127113 compound 57 Drugs 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 150000001924 cycloalkanes Chemical class 0.000 description 1
- PFWWSGFPICCWGU-UHFFFAOYSA-N cyclopropanesulfonyl chloride Chemical group ClS(=O)(=O)C1CC1 PFWWSGFPICCWGU-UHFFFAOYSA-N 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- FRYHCSODNHYDPU-UHFFFAOYSA-N ethanesulfonyl chloride Chemical group CCS(Cl)(=O)=O FRYHCSODNHYDPU-UHFFFAOYSA-N 0.000 description 1
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 description 1
- 238000003810 ethyl acetate extraction Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 230000023266 generation of precursor metabolites and energy Effects 0.000 description 1
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
- XJTQJERLRPWUGL-UHFFFAOYSA-N iodomethylbenzene Chemical compound ICC1=CC=CC=C1 XJTQJERLRPWUGL-UHFFFAOYSA-N 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- FMKOJHQHASLBPH-UHFFFAOYSA-N isopropyl iodide Chemical compound CC(C)I FMKOJHQHASLBPH-UHFFFAOYSA-N 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 231100000515 lung injury Toxicity 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 125000006578 monocyclic heterocycloalkyl group Chemical group 0.000 description 1
- YCJZWBZJSYLMPB-UHFFFAOYSA-N n-(2-chloropyrimidin-4-yl)-2,5-dimethyl-1-phenylimidazole-4-carboxamide Chemical compound CC=1N(C=2C=CC=CC=2)C(C)=NC=1C(=O)NC1=CC=NC(Cl)=N1 YCJZWBZJSYLMPB-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- IOMMMLWIABWRKL-WUTDNEBXSA-N nazartinib Chemical compound C1N(C(=O)/C=C/CN(C)C)CCCC[C@H]1N1C2=C(Cl)C=CC=C2N=C1NC(=O)C1=CC=NC(C)=C1 IOMMMLWIABWRKL-WUTDNEBXSA-N 0.000 description 1
- 230000003988 neural development Effects 0.000 description 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000005311 nuclear magnetism Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 description 1
- 230000005305 organ development Effects 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 102000004164 orphan nuclear receptors Human genes 0.000 description 1
- 108090000629 orphan nuclear receptors Proteins 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000005968 oxazolinyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- OAHKWDDSKCRNFE-UHFFFAOYSA-N phenylmethanesulfonyl chloride Chemical group ClS(=O)(=O)CC1=CC=CC=C1 OAHKWDDSKCRNFE-UHFFFAOYSA-N 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- KPBSJEBFALFJTO-UHFFFAOYSA-N propane-1-sulfonyl chloride Chemical group CCCS(Cl)(=O)=O KPBSJEBFALFJTO-UHFFFAOYSA-N 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 210000003752 saphenous vein Anatomy 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 125000003554 tetrahydropyrrolyl group Chemical group 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- GRGCWBWNLSTIEN-UHFFFAOYSA-N trifluoromethanesulfonyl chloride Chemical compound FC(F)(F)S(Cl)(=O)=O GRGCWBWNLSTIEN-UHFFFAOYSA-N 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides aBenzo-multi-ring thiazoline amide compounds and application thereof, wherein the benzo-multi-ring thiazoline amide compounds have a structure shown in the following formula I:the method comprises the steps of carrying out a first treatment on the surface of the Wherein the ring A is selected from any one of C5-C8 cyclodiene, C4-C8 epoxydiene or C6-C10 aromatic ring; the B ring is selected from any one of substituted or unsubstituted C6-C12 aryl, substituted or unsubstituted C4-C12 nitrogen-containing heteroaryl and substituted or unsubstituted C4-C12 oxygen-containing heteroaryl; r is R 1 、R 2 Independently selected from any one of hydrogen, substituted or unsubstituted C1-C10 straight or branched chain alkyl, substituted or unsubstituted C7-C10 arylalkyl, substituted acyl and substituted sulfonyl. The benzo-polycyclic thiazoline amide compound provided by the invention can effectively inhibit the activities of COUP-TFII and NRF2, and has an excellent inhibition effect on the proliferation of prostate cancer cells.
Description
Technical Field
The invention belongs to the field of pharmaceutical chemistry, and particularly relates to a benzo-multi-ring thiazoline amide compound and application thereof, in particular to a benzo-multi-ring thiazoline amide compound with high activity and application thereof.
Background
And regulating the growth and development of the organism and the cell differentiation, thereby affecting various physiological and metabolic processes in the body. Chicken ovalbumin upstream promoter transcription factor 2 (chicken ovalbumin upstream promoter transcription factor 2, coup-TFII) is one of the important members of the nuclear receptor family. The COUP-TF family includes two highly homologous subtypes, COUP-TFI and COUP-TFII, located on chromosomes 5 and 15, respectively, also referred to as nuclear receptor 2 families 1 and 2 (NR 2F1 and NR2F 2). COUP-TF is currently considered to be an orphan nuclear receptor because no ligand has been identified for its specific binding.
Current studies indicate that COUP-TFI plays an important role in neural development and COUP-TFII plays an important role in organ development, respectively. Further research shows that COUP-TFII plays an important role in various aspects of the physiological growth and development process of the organism, can regulate various signal paths, and participates in controlling tumor growth, angiogenesis, regeneration of organism tissues or cells and the like.
It is worth mentioning that the expression of COUP-TFII is abnormally up-regulated in the states of embryo development stage, tissue regeneration, diseases and the like; whereas in normal tissue or body maturation stage, COUP-TFII expression is maintained at a lower level. The current research result also shows that the COUP-TFII gene is knocked out from adult mice, and the mice do not show abnormal physiological phenomena such as phenotype change and the like. This demonstrates to some extent that inhibition of COUP-TFII does not produce toxic side effects. Therefore, small molecule drugs which target binding and inhibit COUP-TFII activity are developed, i.e. have practical and potential feasibility.
COUP-TFII is a necessary condition for angiogenesis during tumor growth, and its abnormal expression can lead to the occurrence and metastasis of cancer. Therefore, COUP-TFII is an ideal completely new target for potential cancer treatment.
NRF2 (nuclear factor E rythroid 2 related factor, nuclear factor E2 related factor) was cloned in 1994 from Moi et al as a factor binding to the nuclear factor E2 repeat of the beta globin gene promoter. Belongs to the CNC family of transcription factors, and contains a leucine zipper structure.
The NRF2/Keap1 (Kelch-like ECH-associated protein 1, kelch-like epichlorohydrin-related protein 1) -ARE (antioxidant response element ) signaling pathway is an endogenous antioxidant signaling pathway of the organism discovered in recent years.
Activation of the NRF2/Keap 1-ARE pathway is one of the important mechanisms for anti-tumorigenesis. Activation of NRF2 enables cancer cells to adapt to adverse microenvironments and high endogenous ROS levels during early stages of tumorigenesis; whereas in rapidly proliferating cells, NRF2 can support intermediary metabolism by promoting nucleotide and amino acid biosynthesis. Studies have shown that low activity NRF2 promotes tumorigenesis, while sustained high activity NRF2 can accelerate cancer progression and tolerance to treatment.
Therefore, the development of the compound which can inhibit COUP-TFII and NRF2 has very important practical value and wide application prospect in tumor treatment.
Disclosure of Invention
Aiming at the defects of the prior art, the invention aims to provide a benzo-multi-ring thiazoline amide compound and application thereof, in particular to a benzo-multi-ring thiazoline amide compound with high activity and application thereof. The benzo-polycyclic thiazoline amide compound provided by the invention can effectively inhibit the activities of COUP-TFII and NRF2, and has an excellent inhibition effect on the proliferation of prostate cancer cells.
In order to achieve the aim of the invention, the invention adopts the following technical scheme:
in a first aspect, the invention provides a benzo-multi-ring thiazoline amide compound, which has a structure shown in the following formula I:
wherein the ring A is selected from any one of C5-C8 cyclodiene, C4-C8 epoxydiene or C6-C10 aromatic ring.
The B ring is selected from any one of substituted or unsubstituted C6-C12 aryl, substituted or unsubstituted C4-C12 nitrogen-containing heteroaryl and substituted or unsubstituted C4-C12 oxygen-containing heteroaryl.
R 1 、R 2 Independently selected from any one of hydrogen, substituted or unsubstituted C1-C10 straight or branched chain alkyl, substituted or unsubstituted C7-C10 arylalkyl, substituted acyl and substituted sulfonyl.
The benzo multi-ring thiazoline amide compound with the specific structure can effectively inhibit the activities of COUP-TFII and NRF2, and has excellent inhibition effect on the proliferation of prostate cancer cells.
Preferably, the substituents of the C6-C12 aryl, C4-C12 nitrogen-containing heteroaryl or C4-C12 oxygen-containing heteroaryl are independently selected from hydroxy, halogen, unsubstituted or R a Substituted C1-C10 straight-chain or branched alkyl, unsubstituted or R a Substituted C1-C10 alkoxy, unsubstituted or R b Substituted C6-C12Aryl, unsubstituted or R b Any one of substituted C5-C12 nitrogen-containing heteroaryl groups.
The R is a Selected from halogen or deuterium, said R b Selected from the group consisting of C1-C10 straight or branched alkyl, C1-C10 haloalkyl, C1-C10 alkoxy,or-COOR c Any one of the above, R c Any one selected from hydrogen, C1-C10 straight-chain alkyl or branched-chain alkyl, C1-C10 alkoxy, C1-C10 alkylamino or C1-C10 heterocyclic group.
Preferably, the substituents of the linear or branched alkyl groups are selected from halogen, hydrogen or deuterium.
Preferably, the acyl, sulfonyl, C1-C10 straight or branched alkyl, C7-C10 arylalkyl substituents are independently selected from C1-C10 straight or branched alkyl, C1-C10 alkoxy, C1-C10 haloalkyl, C3-C10 cycloalkyl, unsubstituted or R d Substituted C6-C12 aryl, unsubstituted or R d Any of the substituted C5-C12 heteroaryl groups; the R is d Any one of halogen, cyano, C1-C10 straight-chain alkyl or branched-chain alkyl.
n is selected from 0, 1 or 2, and n is 0, where no group is present and X is directly attached to the other end.
Wherein Y is selected from-ch=or-n=, and Z' is selected from-O-or-NH-.
R 3 、R 4 Independently selected from the group consisting of-H, -OH, -OMe, -OCD 3 、-F、-Cl、-CF 3 、Any one of the following.
Z is selected from-CH=or-N=.
The R is f Selected from the group consisting of-H, -Me, -Et, -i-Pr, -n-Bu, -i-Bu, -CH 2 -CHEt 2 、-(CH 2 ) 2 -OMe、-(CH 2 ) 2 -NMe 2 Or (b)Any one of them; />Representing the attachment site of the group.
Preferably, said R 1 、R 2 Independently selected from-H, -Me, -CD 3 、-Et、-i-Pr、-Bn、Any one of the following.
wherein ,Rg Selected from-Me or MeOCH 2 -,R h Selected from-Me, -Et, -n-Pr, -i-Bu, -CF 3 、-Bn、Or->Any one of them; r is R i Selected from any one of-H, -Me, -F or-CN.
Preferably, the benzo-polycyclic thiazoline amide compound is selected from any one of the following formulas 1 to 58:
illustratively, the compounds of formula I may be prepared by the steps of:
the initial compound I-1 is subjected to two-step substitution to obtain a compound III, then a ring is closed to obtain an intermediate M, and the intermediate M is subjected to condensation to obtain the compound shown in the formula I.
In a second aspect, the present invention provides stereoisomers of the benzomulti-ring thiazoline amides described above, pharmaceutically acceptable salts thereof, or pharmaceutical compositions comprising the same.
Preferably, the pharmaceutical composition further comprises pharmaceutically acceptable pharmaceutical excipients.
In a third aspect, the invention provides the use of a benzomulti-ring thiazoline amide compound as described above or a stereoisomer of a benzomulti-ring thiazoline amide compound as described above, a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the same, for the manufacture of a medicament for the treatment and/or prevention of a disease associated with excessive activity of COUP-TFII or overexpression of COUP-TFII.
Preferably, the invention provides the use of a benzo-multi-ring thiazoline amide compound as described above or a stereoisomer of a benzo-multi-ring thiazoline amide compound as described above, a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the same, for the preparation of a COUP-TFII inhibitor for the purpose of diagnosis or treatment of non-diseases.
Preferably, the disease associated with excessive COUP-TFII activity or COUP-TFII overexpression comprises prostate cancer.
In a fourth aspect, the present invention also provides the use of a benzomulti-ring thiazoline amide compound as described above or a stereoisomer of a benzomulti-ring thiazoline amide compound as described above, a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the same, for the preparation of a medicament for the treatment and/or prevention of a disease associated with NRF2 over-activity or NRF2 over-expression.
Preferably, the diseases related to the excessive activity of NRF2 or the over expression of NRF2 comprise liver diseases such as NASH and drug liver injury, respiratory diseases such as lung injury and pulmonary fibrosis, and malignant tumors such as lung cancer, pancreatic cancer, liver cancer, colorectal cancer and prostate cancer.
Compared with the prior art, the invention has the following beneficial effects:
The invention provides a benzo multi-ring thiazoline amide compound with a specific structure, which can effectively inhibit the activities of COUP-TFII and NRF2 and has an excellent inhibition effect on the proliferation of prostate cancer cells.
Detailed Description
In order to further describe the technical means adopted by the present invention and the effects thereof, the following describes the technical scheme of the present invention in combination with the preferred embodiments of the present invention, but the present invention is not limited to the scope of the embodiments.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. The terminology used herein in the description of the invention is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention.
The term "pharmaceutically acceptable salt" means that the compound can be converted by conventional means into the corresponding salt, which is chemically or physically compatible with the other ingredients comprising the pharmaceutical dosage form, and physiologically compatible with the recipient. The salts may be acid and/or base salts of the compounds with inorganic and/or organic acids and/or with inorganic and/or organic bases, and also include zwitterionic salts (inner salts) and also include quaternary ammonium salts, such as alkylammonium salts. These salts may be obtained directly in the final isolation and purification of the compounds. Or by appropriately mixing the compound of the present invention or a stereoisomer or solvate thereof with a certain amount of an acid or a base. These salts may be obtained by precipitation in solution and collected by filtration, or recovered after evaporation of the solvent, or by reaction in an aqueous medium and then cooled and dried. In particular, the salt is preferably a water-soluble pharmaceutically acceptable non-toxic acid addition salt, examples being salts of amino groups with inorganic acids (such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid) or with organic acids (such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid), or by using other methods conventional in the art (e.g. ion exchange methods).
The term "alkyl" refers to a radical containing a primary (positive) carbon atom,Or secondary carbon atoms, or tertiary carbon atoms, or quaternary carbon atoms, or combinations thereof. The phrase containing the term, for example, "C1-C3 alkyl" refers to an alkyl group containing 1 to 3 carbon atoms, which may be, for each occurrence, independently of each other, C1 alkyl, C2 alkyl, C3 alkyl. Suitable examples include, but are not limited to: methyl (Me, -CH) 3 ) Ethyl (Et, -CH) 2 CH 3 ) 1-propyl (n-Pr, n-propyl, -CH 2 CH 2 CH 3 ) 2-propyl (i-Pr, i-propyl, -CH (CH) 3 ) 2 )。
The term "heterocycloalkyl" refers to a non-aromatic cyclic group in which one or more of the atoms making up the ring is a heteroatom and the remainder is carbon, including but not limited to nitrogen, oxygen, sulfur, and the like. Preferred heterocycloalkyl groups are 3-10 membered saturated heterocycloalkyl groups. Unless specifically indicated otherwise in this specification, heterocycloalkyl groups may be monocyclic ("monocyclic heterocycloalkyl"), or bicyclic, tricyclic or more ring systems which may include a fused, bridged or spiro ring system (e.g., a bicyclic system ("bicyclic heterocycloalkyl"). Heterocycloalkyl bicyclic ring system may include one or more heteroatoms in one or both rings, and saturated.
The term "alkoxy" refers to a group having an-O-alkyl group, i.e. an alkyl group as defined above, attached to the parent core structure via an oxygen atom. The phrase containing the term, for example, "C1-C3 alkoxy" means that the alkyl moiety contains 1 to 3 carbon atoms.
The term "aryl" refers to an aromatic hydrocarbon radical derived from the removal of one hydrogen atom on the basis of an aromatic ring compound, which may be a monocyclic aryl radical, or a fused ring aryl radical, or a polycyclic aryl radical, at least one of which is an aromatic ring system for a polycyclic species. Preferred aryl groups are 6-10 membered aryl groups, which may be selected from phenyl and naphthyl, as examples.
The term "heteroaryl" refers to an aryl group containing heteroatoms, which may be a single ring or a fused ring, independently selected from N, O and S, preferably 5-12 membered heteroaryl groups, including but not limited to pyrrolyl, furanyl, thienyl, imidazolyl, oxazolyl, isoxazolyl, pyrazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, quinolinyl, isoquinolinyl, triazolyl, tetrahydropyrrolyl. In one embodiment, a 5-6 membered monocyclic heteroaryl group typically containing 1 or more heteroatoms independently selected from N, O and S. Exemplary 5-membered heteroaryl groups containing one heteroatom, such as "5-membered heteroaryl" unless otherwise specified, include, but are not limited to, pyrrolyl, furanyl, and thienyl; exemplary 5-membered heteroaryl groups containing two heteroatoms include, but are not limited to, imidazolyl, pyrazolyl, oxazolinyl, isoxazolyl, thiazolyl, and isothiazolyl; exemplary 5-membered heteroaryl groups containing three heteroatoms include, but are not limited to, triazolyl, thiadiazolyl; exemplary 5-membered heteroaryl groups containing four heteroatoms include, but are not limited to, tetrazolyl.
In the various parts of the invention, linking substituents are described. When the structure clearly requires a linking group, the markush variables recited for that group are understood to be linking groups. For example, if the structure requires a linking group and the markush group definition for that variable enumerates an "alkyl" or "aryl" group, it will be understood that the "alkyl" or "aryl" represents a linked alkylene group or arylene group, respectively. In some specific structures, when an alkyl group is explicitly represented as a linking group, then the alkyl group represents a linked alkylene group, e.g., the alkyl in the group "-C1-C3 haloalkyl" is to be understood as alkylene.
Furthermore, the term "comprising" is an open-ended limitation and does not exclude other aspects, i.e. it includes the content indicated by the invention.
Unless otherwise indicated, the present invention employs conventional methods of mass spectrometry, nuclear magnetism, and the like to identify compounds, and the procedures and conditions may be referred to procedures and conditions conventional in the art.
As will be appreciated by those skilled in the art, the present application describes "as used in the structural formula of a group" in accordance with convention used in the art " By "is meant that the corresponding group is attached to other fragments, groups in the compound through that site. The above preferred conditions can be arbitrarily combined on the basis of not deviating from the common knowledge in the art, and thus, each preferred embodiment of the present invention can be obtained.
The terms "halo", "halogen" refer to halogen atoms or are substituted with halogen atoms including fluorine, chlorine, bromine or iodine atoms.
The term "cyclodiene" refers to a cycloalkane having two double bonds, such as cyclopentadiene, cyclohexadiene, cycloheptadiene, or cyclononadiene; the term "epoxydiene" refers to a structure in which at least one carbon atom is replaced by an oxygen atom on the basis of the term "cyclodiene".
The reagents and materials used in the present invention are commercially available.
Synthesis of intermediate M-a:
step M-1: compound I-a (8.0 g,49.6 mmol) and pyridine (4.31 g,54.56 mmol) were added to dichloromethane (20 mL), methanesulfonyl chloride (5.68 g,49.6 mmol) was slowly added under ice-bath conditions, and then stirred overnight at 20 ℃. After the reaction, adding 1.0M sodium hydroxide solution to adjust the pH value of the system to be between 11 and 12, extracting with dichloromethane and water, adjusting the pH value of the obtained water phase part to be between 5 and 6 with 1.0M hydrochloric acid, filtering and drying to obtain a yellow solid compound II-a (9.7 g, yield 82%). LCMS [ M+H ] + = 240.1。
Step M-2: compound II-a (9.7 g,40.7 mmol) and potassium carbonate (11.2 g,81.4 mmol) were added to N, N-dimethylformamide (20 mL) under ice-bath conditionsA mixed solution of methyl iodide (6.9 g,48.7 mmol) and N, N-dimethylformamide (10 mL) was slowly added, followed by stirring overnight at 20 ℃. After the reaction, the reaction solution was added to a sufficient amount of water and stirring was continued for 30 minutes, and then filtered and dried to obtain a yellow solid compound III-a (10.1. 10.1 g, yield 99%). LCMS [ M+H] + = 254.1。
Step M-3: compound III-a (3.0 g,11.86 mmol) and elemental iodine (4.5 g,17.79 mmol) were added to ethanol (20 mL), 95 o Stirring for 30 min under C, then adding thiourea (1.80 g,23.72 mmol), 95 o Stirring overnight under the condition C, adding 1.0M sodium hydroxide solution to quench the reaction after the reaction is finished, regulating the pH value of the system to 10-11, adding water (20 mL), stirring at 20 ℃ for 30 minutes, filtering, and drying to obtain a coffee solid intermediate M-a (2.38 g, yield 64%). LCMS [ M+H] + = 310.1。
Example 1:
the synthetic route is as follows:
intermediate M-a (92.7 mg,0.3 mmol), starting compound 1-a (60 mg,0.3 mmol), N, N-diisopropylethylamine (116 mg, 0.9 mmol) and 2- (7-azobenzotriazole) -N, N, N ', N' -tetramethylurea hexafluorophosphate (171 mg,0.45 mmol) were added to N, N-dimethylformamide (1.5 mL) and stirred overnight at 20 ℃. After the completion of the reaction, compound 1 was purified by reverse phase column chromatography to give yellow solid (27, mg, yield 18%). LCMS [ M+H ] + = 491.1。
1H NMR (400 MHz, DMSO-d6) δ 12.81 (s, 1H), 8.71 (s, 1H), 8.26-8.21 (m, 4H), 8.09 (d, J = 6.0 Hz, 1H), 7.92 (t, J = 6.0 Hz, 1H), 7.72 (d, J = 6.0 Hz, 1H), 7.41 (t, J = 6.0 Hz, 1H), 7.33-7.30 (m, 2H), 3.23 (s, 3H), 3.02-2.98 (m, 4 H), 2.95 (s, 3H)。
Example 2:
the synthetic route is as follows:
intermediate M-a (927 mg,3 mmol), starting compound 2-a (600 mg,3 mmol), N, N-diisopropylethylamine (1.16 g,9 mmol) and 2- (7-azobenzotriazole) -N, N, N ', N' -tetramethylurea hexafluorophosphate (1.71 g,4.5 mmol) were added to N, N-dimethylformamide (15 mL), followed by stirring overnight at 20 ℃. After the completion of the reaction, the compound 2-b was purified by reverse phase column chromatography to give a pink solid (840, mg, yield 57%). LCMS [ M+H] + = 493.1。
1H NMR (400 MHz, DMSO-d6) δ 12.79 (s, 1H), 8.03 (d, J = 6.0 Hz, 2H), 7.74 (d, J = 6.0 Hz, 2H), 7.70 (d, J = 6.0 Hz, 1H), 7.31 (d, J = 6.0 Hz, 2H), 3.22 (s, 3H), 3.02-2.97 (m, 4H), 2.95 (s, 3H).
Compound 2-b (150 mg,0.3 mmol), compound 2-c (74 mg,0.36 mmol), [1,1' -bis (diphenylphosphine) ferrocene]Palladium dichloride dichloromethane complex (25 mg,0.03 mmol) and sodium carbonate (63.6 mg,0.6 mmol) were added to a mixed solvent of 1, 4-dioxane (5 mL) and water (0.5 mL), and the mixture was heated to 100℃under nitrogen to react overnight. After the completion of the reaction, ethyl acetate (20 mL) was added to dilute, filter and extract, and the organic phase was concentrated and purified by column chromatography to give compound 2 as a yellow solid (104, mg, yield 70%). LCMS [ M+H] + = 491.1。
1H NMR (400 MHz, DMSO-d6) δ 12.83 (s, 1H), 8.68-8.66 (m, 2H), 8.25 (d, J = 6.0 Hz, 2H), 7.98 (d, J = 6.0 Hz, 2H), 7.81-7.79 (m, 2H), 7.72 (d, J = 6.0 Hz, 1H), 7.32 (d, J = 6.0 Hz, 2H), 3.23 (s, 3H), 3.04-2.98 (m, 4 H), 2.96 (s, 3H)。
Example 3:
the synthetic route is as follows:
referring to example 2, compound 2-c was replaced with an equivalent amount of compound 3-a, and compound 3 was synthesized as a yellow solid (27, mg, yield 18%). LCMS [ M+H ] + = 491.1。
1H NMR (400 MHz, DMSO-d6) δ 12.81 (s, 1H), 8.99 (s, 1H), 8.62-8.61 (m, 1H), 8.24 (d, J = 6.0 Hz, 2H), 8.18 (d, J = 6.0 Hz, 1H), 7.92 (d, J = 6.0 Hz, 2H), 7.72 (d, J = 6.0 Hz, 1H), 7.53-7.50 (m, 1H), 7.32 (d, J = 6.0 Hz, 2H), 3.23 (s, 3H), 3.03-2.98 (m, 4 H), 2.96 (s, 3H)。
Example 4:
the synthetic route is as follows:
compound 2 (20 mg,0.04 mmol) and 2, 3-dichloro-5, 6-dicyanobenzoquinone (14 mg,0.06 mmol) were added to 1, 2-dichloroethane (3 mL), and the mixture was heated to 60℃under nitrogen to react overnight. After the completion of the reaction, N-dimethylformamide (5 mL) was added thereto for dilution, and the mixture was purified by reverse phase column chromatography to give compound 4 (12, 12 mg, yield 61%) as a yellow solid. LCMS [ M+H] + = 489.1。
1H NMR (400 MHz, DMSO-d6) δ 12.22 (s, 1H), 8.69 - 8.66 (m, 2H), 8.58 (d, J = 6.8 Hz, 1H), 8.32 (d, J = 6.0 Hz, 2H), 8.14 (d, J = 6.8 Hz, 1H), 8.09 (s, 1H), 8.02 (d, J = 6.0 Hz, 2H), 7.86 (d, J = 6.8 Hz, 1H), 7.82 (d, J = 4.4 Hz, 2H), 7.74 - 7.71 (m, 1 H), 3.36 (s, 3H), 3.01 (s, 3H)。
Example 5:
the synthetic route is as follows:
referring to example 2, the compound 2-a was replaced with an equivalent of 5-a and the compound 2-c was replaced with an equivalent of 3-a, to thereby obtain a yellow solid compound 5 (100 mg, yield 91%). LCMS [ M+H] + =521.1。
1H NMR (400 MHz, DMSO-d6) δ 11.95 (s, 1H), 9.02 (s, 1H), 8.63 (d, J = 3.3 Hz, 1H), 8.20 (d, J = 6.0 Hz, 1H), 7.83 (d, J = 6.0 Hz, 1H), 7.69 (d, J = 6.0 Hz, 1H), 7.55 - 7.52 (m, 2H), 7.45 (d, J = 6.0 Hz, 1H), 7.32 - 7.30 (m, 2H), 4.06 (s, 3H), 3.24 (s, 3H), 3.03 - 2.99 (m, 4H), 2.96 (s, 3H)。
Example 6:
the synthetic route is as follows:
compound II-a (2.0 g,8.37 mmol) and elemental iodine (2.1 g,8.37 mmol) were added to ethanol (20 mL), stirred at 95℃for 30 min, then thiourea (1.3 g,16.7 mmol) was added, stirred at 95℃overnight, after completion of the reaction, concentrated, and purified by reverse phase column chromatography to give compound 6-a (2.1 g, yield 85%) as a yellow solid. LCMS [ M+H ]] + = 296.1。
Compound 6-a (2.1 g,7.12 mmol) and potassium carbonate (1.96 g,14.2 mmol) were added to N, N-dimethylformamide (20 mL), followed by di-tert-butyl dicarbonate (1.7 g,7.83 mmol), stirred overnight at 40℃and after completion of the reaction, water was added (100 mL) dilution, ethyl acetate extraction, concentration of the organic phase, and purification by column chromatography gave compound 6-b as a gray solid (2 g, 71.4% yield). LCMS [ M+H ]] + = 396.1。
Then referring to example 2, compound 2-a was replaced with an equivalent of compound 6-c, compound M-a was replaced with an equivalent of compound 6-b, and compound 2-c was replaced with an equivalent of compound 6-e to give compound 6-f, which was deprotected to synthesize compound 6 as a yellow solid (700 mg, yield 83.8%). LCMS [ M+H ]] + = 507.1。
1H NMR (400 MHz, DMSO-d6) δ 11.93 (s, 1H), 9.73 (s, 1H), 9.02 (s, 1H), 8.63 (d, J = 4.8 Hz, 1H), 8.20 (d, J = 8.4 Hz, 1H), 7.83 (d, J = 8.0 Hz, 1H), 7.64 (d, J = 8.0 Hz, 1H), 7.55 - 7.52 (m, 2H), 7.45 (d, J = 8.4 Hz, 1H), 7.13 - 7.11 (m, 2H), 4.06 (s, 3H), 3.00 - 2.94 (m, 7H)。
Example 7:
the synthetic route is as follows:
referring to the synthesis method of intermediate M-a, methyl iodide was replaced with an equivalent amount of trideuterated methyl iodide to obtain intermediate M-b, and then referring to example 2, compound 2-a was replaced with an equivalent amount of compound 7-a, compound M-a was replaced with an equivalent amount of M-b, and compound 2-c was replaced with an equivalent amount of 7-c, to obtain compound 7 as a yellow solid (80 mg, yield 40%). LCMS [ M+H] + = 524.1。
1H NMR (400 MHz, DMSO-d6) δ 11.95 (s, 1H), 9.01 (s, 1H), 8.63 (d, J = 3.0 Hz, 1H), 8.20 (d, J = 6.0 Hz, 1H), 7.83 (d, J = 6.0 Hz, 1H), 7.69 (d, J = 5.7 Hz, 1H), 7.54 - 7.52 (m, 2H), 7.45 (d, J = 5.7 Hz, 1H),7.32 - 7.29 (m, 2H), 4.05 (s, 3H), 3.02 - 2.98 (m, 4H), 2.96 (s, 3H)。
Example 8:
the synthetic route is as follows:
referring to the synthesis of intermediate M-a, methyl iodide was replaced with an equivalent amount of ethyl iodide to give intermediate M-c, and then referring to example 2, compound 2-a was replaced with an equivalent amount of compound 8-a, compound M-a was replaced with an equivalent amount of M-c, and compound 2-c was replaced with an equivalent amount of 8-c, to thereby obtain compound 8 as a yellow solid (10.4. 10.4 mg, yield 41%). LCMS [ M+H ] + = 535.1。
1H NMR (400 MHz, DMSO-d6) δ 11.95 (s, 1H), 9.01 (s, 1H), 8.63 (d, J = 4.8 Hz, 1H), 8.20 (d, J = 8.0 Hz, 1H), 7.84 (d, J = 8.0 Hz, 1H), 7.71 (d, J = 8.0 Hz, 1H), 7.55 - 7.52 (m, 2H), 7.45 (d, J = 8.4 Hz, 1H), 7.27 (d, J = 9.6 Hz, 2H), 4.06 (s, 3H), 3.66 (q, J = 7.2 Hz, 2H), 3.04 - 2.99 (m, 7H), 1.02 (t, J = 7.2 Hz, 3H)。
Example 9:
the synthetic route is as follows:
referring to the synthesis of intermediate M-a, methyl iodide was replaced with an equivalent amount of 2-iodopropane to give intermediate M-d, and then referring to example 2, compound 2-a was replaced with an equivalent amount of compound 9-a, compound M-a was replaced with an equivalent amount of M-d, and compound 2-c was replaced with an equivalent amount of 9-c, to thereby obtain yellow solid compound 9 (10.4. 10.4 mg, yield 41%). LCMS [ M+H] + = 549.1。
1H NMR (400 MHz, DMSO-d6) δ 11.95 (s, 1H), 9.01 (s, 1H), 8.63 (d, J = 4.0 Hz, 1H), 8.20 (d, J = 7.2 Hz, 1H), 7.85 (d, J = 8.0 Hz, 1H), 7.72 (d, J = 8.4 Hz, 1H), 7.55 - 7.52 (m, 2H), 7.46 (d, J = 8.0 Hz, 1H), 7.18 (d, J = 7.2 Hz, 2H), 4.36 - 4.29 (m, 1H), 4.06 (s, 3H), 3.07 - 3.00 (m, 7H), 1.10 (d, J = 6.8 Hz, 6H)。
Example 10:
the synthetic route is as follows:
referring to the synthesis method of intermediate M-a, methyl iodide was replaced with an equivalent amount of benzyl iodide to obtain intermediate M-e, and then referring to example 2, compound 2-a was replaced with an equivalent amount of compound 10-a, compound M-a was replaced with an equivalent amount of M-e, and compound 2-c was replaced with an equivalent amount of 10-c, to obtain compound 10 as a yellow solid (23.2 mg, yield 51%). LCMS [ M+H] + = 597.1。
1H NMR (400 MHz, DMSO-d6) δ 11.93 (s, 1H), 9.01 (s, 1H), 8.62 (d, J = 4.8 Hz, 1H), 8.20 (d, J = 8.0 Hz, 1H), 7.82 (d, J = 8.0 Hz, 1H), 7.61 (d, J = 8.4 Hz, 1H), 7.54 - 7.51 (m, 2H), 7.44 (d, J = 8.0 Hz, 1H), 7.31 - 7.25 (m, 6H), 7.21 (q, J = 4.4 Hz, 1H), 4.86 (s, 2H), 4.04 (s, 3H), 3.10 (s, 3H), 2.99 - 2.92 (m, 4H)。
Example 11:
the synthetic route is as follows:
referring to example 2, compound 2-a was replaced with an equivalent of compound 11-a and compound 2-c was replaced with an equivalent of 11-c, to thereby obtain compound 11 as a yellow solid (50 mg, yield 22%). LCMS [ M+H] + = 527.1。
1H NMR (400 MHz, DMSO-d6) δ 11.93 (s, 1H), 9.01 (s, 1H), 8.63 (d, J = 2.7 Hz, 1H), 8.20 (d, J = 6.0 Hz, 1H), 7.84 (d, J = 6.0 Hz, 1H), 7.69 (d, J = 6.0 Hz, 1H), 7.54-7.51 (m, 2H), 7.45 (d, J = 5.7Hz, 1H), 7.32 - 7.29 (m, 2H), 3.02 - 2.98 (m, 4H), 2.96 (s, 3H)。
Example 12:
the synthetic route is as follows:
compound 5 (50 mg,0.1 mmol) was added to dichloromethane (3 mL), boron tribromide (0.2 mL) was added under ice-bath, then stirred at 20℃for 30 minutes, after the reaction was completed, methanol was added to quench the reaction, and the reaction mixture was concentrated, and purified by reverse phase column chromatography to give compound 12 (20 mg, yield 39.5%) as a yellow solid. LCMS [ M+H ] + = 507.1。
1H NMR (400 MHz, DMSO-d6) δ 12.08 (s, 1H), 8.93 (s, 1H), 8.63 (s, 1H), 8.16 - 8.11 (m, 2H), 7.43 (d, J = 6.0 Hz, 1H), 7.54 - 7.51 (m, 1H), 7.39 - 7.31 (m, 4H), 3.24 (s, 3H), 3.04 - 2.99 (m, 4H), 2.97 (s, 3H)。
Example 13:
the synthetic route is as follows:
referring to example 12, compound 5 was replaced with an equivalent of compound 7 to yield compound 13 as a yellow solid (200 mg, 93% yield). LCMS [ M+H] + = 510.1。
1H NMR (400 MHz, DMSO-d6) δ 12.25 (s, 1H), 9.13 (s, 1H), 8.80 (d, J = 3.6 Hz,1H), 8.57 (d, J = 6.6 Hz,1H), 8.17 (d, J = 6.0 Hz, 1H), 7.89 (t, J = 5.7 Hz, 1H), 7.71 (d, J = 6.0 Hz, 1H), 7.45-7.41 (m, 2H), 7.33 - 7.31 (m, 2H), 3.03 - 2.98 (m, 4H), 2.96 (s, 3H)。
Example 14:
the synthetic route is as follows:
referring to example 2, compound 2-b was replaced with an equivalent of 14-a (i.e., 5-b) and compound 2-c was replaced with an equivalent of 14-b, to thereby obtain compound 14 (201, mg, yield 89.5%) as a yellow solid. LCMS [ M+H] + = 589.1。
1H NMR (400 MHz, DMSO-d6) δ 12.05 (s, 1H), 9.33 (s, 1H), 9.04 (s, 1H), 8.62 (s, 1H), 7.84 (d, J = 5.6 Hz, 1H), 7.70 (d, J = 6.0 Hz, 1H), 7.64 (s, 1H), 7.58 (d, J = 6.0 Hz, 1H), 7.33 - 7.31 (m, 2H), 4.08 (s, 3H), 3.24 (s, 3H), 3.04 - 3.00 (m, 4H), 2.97 (s, 3H)。
Example 15:
the synthetic route is as follows:
referring to example 2, compound 2-b was replaced with an equivalent of 15-a (i.e., 7-b) and compound 2-c was replaced with an equivalent of 15-b, thus obtaining compound 15 (60 mg, yield 37.6%) as a yellow solid. LCMS [ M+H] + = 592.1。
1H NMR (400 MHz, DMSO-d6) δ 12.00 (s, 1H), 9.31 (s, 1H), 9.01 (s, 1H), 8.60 (s, 1H), 7.83 (d, J = 6.4 Hz, 1H), 7.68 (d, J = 6.0 Hz, 1H), 7.62 (s, 1H), 7.56 (d, J = 5.6 Hz, 1H), 7.31 - 7.29 (m, 2H), 4.06 (s, 3H), 3.02 - 2.98 (m, 4H), 2.95 (s, 3H)。
Example 16:
the synthetic route is as follows:
referring to example 2, compound M-a was replaced with an equivalent of M-b, compound 2-a was replaced with an equivalent of 16-a, and compound 2-c was replaced with an equivalent of 16-c, to thereby obtain compound 16 (55.9. 55.9 mg, yield 24.5%) as a yellow solid. LCMS [ M+H] + = 566.1。
1H NMR (400 MHz, DMSO-d6) δ 12.85 (s, 1H), 9.14 (s, 1H), 8.46 – 8.35 (m, 1H), 8.28 (d, J = 8.0 Hz, 2H), 8.15 (d, J = 8.4 Hz, 1H), 8.01 (d, J = 8.4 Hz, 2H), 7.73 (d, J = 8.0 Hz, 1H), 7.34 - 7.31 (m, 2H), 4.37 (q, J = 7.2 Hz, 2H), 3.05 - 2.97 (m, 7H), 1.35 (t, J = 7.2 Hz, 3H)。
Example 17:
the synthetic route is as follows:
compound 17-a (i.e., 16-b,690 mg, 1.39 mmol), pinacol biborate (708 mg,2.79 mmol), 1' -bis (diphenylphosphine) ferrocene]Palladium dichloride (102 mg,0.14 mmol) and potassium acetate (273 mg,2.79 mmol) were added to 1, 4-dioxane (10 mL), stirred at 10℃for 6 hours, after completion of the reaction, concentrated and purified by column chromatography to give compound 17-b (750 mg, yield 99.4%) as a red oil, LCMS: [M+H] + = 543.1。
Compound 17-b (120 mg,0.22 mmol), compound 17-c (72 mg,0.33 mmol), [1,1' -bis (diphenylphosphine) ferrocene]Palladium dichloride (24 mg,0.022 mmol) and potassium carbonate (92 mg,0.66 mmol) were added to a mixed solvent of 1, 4-dioxane (4 mL) and water (0.5 mL), stirred overnight at 95℃and after completion of the reaction, concentrated and purified by column chromatography to give compound 17 (24.2 mg, yield 19.8%) as a yellow solid, LCMS: [ M+H] + = 552.1。
1H NMR (400 MHz, DMSO-d6) δ 12.84 (s, 1H), 9.20 (s, 1H), 8.46 – 8.35 (m, 1H), 8.33 (d, J = 8.4 Hz, 2H), 8.27 (d, J = 8.4 Hz, 3H), 7.73 (d, J = 8.0 Hz, 1H), 7.34 - 7.31 (m, 2H), 3.91 (s, 3H), 3.04 - 2.97 (m, 7H)。
Example 18:
the synthetic route is as follows:
referring to example 2, compound M-a was replaced with an equivalent of M-b, compound 2-a was replaced with an equivalent of 18-a, and compound 2-c was replaced with an equivalent of 18-c, to thereby obtain compound 18 (57.1. 57.1 mg, yield 13.6%) as a yellow solid. LCMS [ M+H] + = 566.1。
1H NMR (400 MHz, DMSO-d6) δ 12.08 (s, 1H), 9.14 (s, 1H), 8.46 (d, J = 8.4 Hz, 1H), 8.28 (d, J = 8.4 Hz, 1H), 8.11 (d, J = 8.0 Hz, 2H), 8.02 (d, J = 8.0 Hz, 2H), 7.75 (d, J = 8.8 Hz, 1H), 7.34 - 7.32 (m, 2H), 4.36 (q, J = 7.2 Hz, 2H), 3.06 - 3.01 (m, 4H), 2.97 (s, 3H), 1.35 (t, J = 7.2 Hz, 3H)。
Example 19:
the synthetic route is as follows:
compound 18 (100 mg,0.18 mmol) was added to a mixture of tetrahydrofuran (2 mL) and ethanol (2 mL), then an aqueous solution of sodium hydroxide (35 mg,0.88 mmol) was added (1 mL), stirred overnight at 45℃and after the reaction was completed, concentrated and purified by column chromatography to give Compound 19 (31.1 mg, yield 32.7%) as a yellow solid, LCMS: [ M+H] + = 538.1。
1H NMR (400 MHz, DMSO-d6) δ 8.88 (s, 1H), 8.32 (d, J = 8.4 Hz, 1H), 8.19 – 8.03 (m, 4H), 7.97 (d, J = 8.0 Hz, 2H), 7.73 (d, J = 8.0 Hz, 1H), 7.64 (d, J = 8.0 Hz, 2H), 7.27 - 7.23 (m, 2H), 3.00 - 2.94 (m, 5H), 2.88 - 2.84 (m, 2H)。
Example 20:
the synthetic route is as follows:
referring to example 2, compound 2-c was replaced with an equivalent amount of 20-c, and thus, compound 20 (346 mg, yield 76%) was synthesized as a yellow solid. LCMS [ M+H ] + = 562.1。
1H NMR (400 MHz, DMSO-d6) δ 12.80 (s, 1H), 8.24 (d, J = 6.0 Hz, 2H), 8.05 (d, J = 6.0 Hz, 2H), 7.91 (d, J = 6.0 Hz, 4H), 7.72 (d, J = 6.0 Hz, 1H), 7.32 (d, J = 6.0 Hz, 2H), 4.38 – 4.27 (m, 2H), 3.24 (s, 3H), 3.02 - 2.98 (m, 4H), 2.96 (s, 3H), 1.33 (t, J = 5.6 Hz, 3H)。
Example 21:
the synthetic route is as follows:
referring to example 2, compound 2-c was replaced with an equivalent amount of 21-c, and yellow solid compound 21 (100 mg, yield 46.7%) was synthesized. LCMS [ M+H] + = 565.1。
1H NMR (400 MHz, DMSO-d6) δ 12.78 (s, 1H), 8.24 (d, J = 6.0 Hz, 2H), 8.06 (d, J = 6.4 Hz, 2H), 7.92 (d, J = 6.0 Hz, 4H), 7.73 (d, J = 6.4 Hz, 1H), 7.32 (d, J = 5.6 Hz, 2H), 4.36 - 4.31 (m, 2H), 3.03 - 2.98 (m, 4H), 2.96 (s, 3H), 1.33 (t, J = 5.6 Hz, 3H)。
Example 22:
the synthetic route is as follows:
synthesis of Compound I-a with respect to intermediate M-a, substituting equivalent amounts of 5-amino-2, 3-dihydro-1H-inden-1-one to give intermediate M-f, further with respect to example 2, substituting equivalent amounts of M-f for Compound M-a and 22-c for Compound 2-c to give Compound 22-d, and further with respect to example 19, substituting equivalent amounts of 22-d for Compound 18 afforded Compound 22 as a yellow solid (10.2. 10.2 mg, yield 26%). LCMS [ M+H] + = 520.1。
1H NMR (400 MHz, DMSO-d6) δ 12.95 (s, 1H), 8.26 (d, J = 8.4 Hz, 2H), 8.05 (d, J = 8.4 Hz, 2H), 7.92 (t, J = 8.4 Hz, 4H), 7.64 (s, 1H), 7.57 (d, J = 8.0 Hz, 1H), 7.41 (d, J = 8.0 Hz, 1H), 3.96 (s, 2H), 3.27 (s, 3H), 2.97 (s, 3H)。
Example 23:
the synthetic route is as follows:
referring to the synthesis of intermediate M-a and example 22, substitution of methyl iodide with an equivalent amount of trideuterated methyl iodide gave intermediate M-g, and referring again to example 2, substitution of compound M-a with an equivalent amount of M-g and substitution of compound 2-c with an equivalent amount of 23-c, yellow solid compound 23 was synthesized (10 mg, 14% yield). LCMS [ M+H] + = 551.1。
1H NMR (400 MHz, CDCl3) δ 10.19 (s, 1H), 8.14 (d, J = 6.0 Hz, 2H), 8.06 (d, J = 6.0 Hz, 2H), 7.54 (d, J = 6.0 Hz, 2H), 7.66 (d, J = 6.0 Hz, 2H), 7.56 (s, 1H), 7.50 (d, J = 6.0 Hz, 1H), 7.29 (d, J = 6.0 Hz, 1H), 7.45 - 7.39 (m, 2H), 3.90 (s, 2H), 2.84 (s, 3H), 1.14 (t, J = 5.2 Hz, 3H)。
Example 24:
the synthetic route is as follows:
referring to the synthesis of intermediate M-a, compound I-a is replaced with an equivalent amount of 2-amino-6, 7,8, 9-tetrahydro-5H-benzo [7 ]]The intermediate M-h was obtained by substituting equivalent amount of trideuterated iodomethane for cycloolefin-5-one and equivalent amount of trideuterated iodomethane, and referring to example 2, compound 24 was synthesized by substituting equivalent amount of M-h for compound M-a and equivalent amount of 24-c for compound 2-c (3.3 mg, yield 18.4%). LCMS [ M+H ] + = 579.1。
1H NMR (400 MHz, DMSO-d6) δ 12.71 (s, 1H), 8.24 (d, J = 8.4 Hz, 2H), 8.07 - 8.04 (m, 3H), 7.97 – 7.89 (m, 4H), 7.42 – 7.31 (m, 1H), 7.29 (s, 1H), 4.34 (q, J = 7.2 Hz, 2H), 3.01 - 2.97 (m, 5H), 2.82 (d, J = 8.0 Hz, 2H), 2.12 - 2.06 (m, 2H), 1.34 (t, J = 7.2 Hz, 3H)。
Example 25:
the synthetic route is as follows:
synthesis of yellow solid compound 25 (2.5 mg, yield 26%) was obtained by substituting equivalent amounts of 7-aminochroman-4-one for compound I-a and equivalent amounts of trideuterated iodomethane for intermediate M-I with reference to intermediate M-a, substituting equivalent amounts of M-I for compound M-a and 25-c for compound 2-c for compound 25-d, and substituting equivalent amounts of compound 25-d for compound 18 with reference to example 19. LCMS [ M+H] + = 539.1。
1H NMR (400 MHz, DMSO-d6) δ 8.23 (d, J = 8.0 Hz, 2H), 8.04 (d, J = 8.0 Hz, 2H), 7.90 (d, J = 8.4 Hz, 2H), 7.85 (d, J = 8.0 Hz, 2H), 7.62 (d, J = 8.4 Hz, 1H), 7.08 (d, J = 8.4 Hz, 1H), 7.00 (s, 1H), 5.53 (s, 2H), 2.95 (s, 3H)。
Example 26:
the synthetic route is as follows:
referring to example 2, compound M-a was replaced with equivalent M-b, compound 2-a was replaced with equivalent 26-a, and compound 2-c was replaced with equivalent 26-c, and then referring to example 19, compound 18 was replaced with equivalent 26-d, so that compound 26 (51.2. 51.2 mg, yield 77%) as a white solid was synthesized. LCMS [ M+H] + = 540.1。
1H NMR (400 MHz, DMSO-d6) δ 12.33 (s, 1H), 8.03 (d, J = 8.0 Hz, 2H), 7.72 (d, J = 8.0 Hz, 1H), 7.64 (d, J = 8.0 Hz, 2H), 7.47 (d, J = 4.0 Hz, 1H), 7.32 - 7.30 (m, 2H), 6.41 (d, J = 4.0 Hz, 1H), 3.90 (s, 3H), 3.02 - 2.96 (m, 7H)。
Example 27:
the synthetic route is as follows:
referring to example 2, compound 2-b was replaced with an equivalent of 27-a (i.e., 16-b) and compound 2-c was replaced with an equivalent of 27-b, thus obtaining compound 27 (50. 50 mg, yield 50.5%) as a yellow solid. LCMS [ M+H] + = 551.1。
1H NMR (400 MHz, DMSO-d6) δ 12.80 (s, 1H), 8.25 (d, J = 6.0 Hz, 2H), 8.07 (d, J = 6.4 Hz, 2H), 7.95 - 7.92 (m, 4H), 7.73 (d, J = 6.0 Hz, 1H), 7.33 - 7.31 (m, 2H), 3.88 (s, 3H), 3.05 - 2.98 (m, 4H), 2.96 (s, 3H)。
Example 28:
the synthetic route is as follows:
referring to example 2, compound 2-b was replaced with an equivalent of 28-a (i.e., 16-b) and compound 2-c was replaced with an equivalent of 28-b, thus obtaining compound 28 (80 mg, yield 76.9%) as a yellow solid. LCMS [ M+H ] + = 579.1。
1H NMR (400 MHz, DMSO-d6) δ 12.80 (s, 1H), 8.25 (d, J = 6.4 Hz, 2H), 8.05 (d, J = 6.4 Hz, 2H), 7.94 - 7.91 (m, 4H), 7.73 (d, J = 6.0 Hz, 1H), 7.33 - 7.30 (m, 2H), 5.19 - 5.13 (m, 1H), 3.05 - 2.98 (m, 4H), 2.96 (s, 3H), 1.34 (d, J = 4.8 Hz, 6H)。
Example 29:
the synthetic route is as follows:
referring to example 2, compound 2-b was replaced with an equivalent of 29-a (i.e., 16-b) and compound 2-c was replaced with an equivalent of 29-b, thus obtaining compound 29 (60 mg, yield 56.3%) as a yellow solid. LCMS [ M+H] + = 593.1。
1H NMR (400 MHz, DMSO-d6) δ12.80 (s, 1H), 8.25 (d, J = 6.4 Hz, 2H), 8.06 (d, J = 6.0 Hz, 2H), 7.93 - 7.90 (m, 4H), 7.73 (d, J = 6.0 Hz, 1H), 7.33 - 7.31 (m, 2H), 4.30 (t, J = 4.8 Hz, 2H), 3.05-2.99 (m, 4H), 2.96 (s, 3H), 1.74 - 1.67 (m, 2H), 1.48 - 1.39 (m, 2H), 0.94 (t, J = 5.4 Hz, 3H)。
Example 30:
the synthetic route is as follows:
referring to example 2, compound 2-b was replaced with an equivalent of 30-a (i.e., 16-b) and compound 2-c was replaced with an equivalent of 30-b, thus obtaining compound 30 (55 mg, yield 51.6%) as a yellow solid. LCMS [ M+H] + = 593.1。
1H NMR (400 MHz, DMSO-d6) δ12.82 (s, 1H), 8.25 (d, J = 8.4 Hz, 2H), 8.08 (d, J = 8.4 Hz, 2H), 7.96 – 7.89 (m, 4H), 7.73 (d, J = 8.0 Hz, 1H), 7.33 (d, J = 7.6 Hz, 1H), 4.10 (d, J = 6.4 Hz, 2H), 3.08 – 2.98 (m, 4H), 2.97 (s, 3H), 2.12 – 1.99 (m, 1H), 0.99 (d, J = 6.8 Hz, 6H)。
Example 31:
the synthetic route is as follows:
referring to example 2, compound 2-b was replaced with an equivalent of 31-a (i.e., 16-b) and compound 2-c was replaced with an equivalent of 31-b, thus obtaining compound 31 (80 mg, yield 71.7%) as a yellow solid. LCMS [ M+H] + = 621.1。
1H NMR (400 MHz, DMSO-d6) δ12.80 (s, 1H), 8.25 (d, J = 6.0 Hz, 2H), 8.05 (d, J = 6.0 Hz, 2H), 7.95 - 7.91 (m, 4H), 7.73 (d, J = 6.0 Hz, 1H), 7.33 - 7.31 (m, 2H), 4.24 (d, J = 4.2 Hz, 2H), 3.05 - 2.98 (m, 4H), 2.96 (s, 3H), 1.68 - 1.62 (m, 1H), 1.46 - 1.38 (m, 4H), 0.92 (t, J = 5.6 Hz, 6H)。
Example 32:
the synthetic route is as follows:
referring to example 2, compound 2-b was replaced with an equivalent of 32-a (i.e., 16-b) and compound 2-c was replaced with an equivalent of 32-b, thus obtaining compound 32 (78 mg, yield 70.2%) as a yellow solid. LCMS [ M+H] + = 595.1。
1H NMR (400 MHz, CDCl3) δ 9.99 (s, 1H), 8.18 (d, J = 8.0 Hz, 2H), 8.03 (d, J = 8.0 Hz, 2H), 7.76 – 7.66 (m, 5H), 7.23 (d, J = 8.0 Hz, 2H), 4.55 – 4.48 (m, 2H), 3.79 – 3.74 (m, 2H), 3.46 (s, 3H), 3.10 – 3.01 (m, 4H), 2.86 (s, 3H)。
Example 33:
the synthetic route is as follows:
referring to example 2, compound 2-b was replaced with an equivalent of 33-a (i.e., 16-b) and compound 2-c was replaced with an equivalent of 33-b, whereby compound 33 (43 mg, yield 66.2%) was synthesized as a yellow solid. LCMS [ M+H ] + = 609.1。
1H NMR (400 MHz, CDCl3) δ 9.97 (s, 1H), 8.18 (d, J = 8.0 Hz, 2H), 8.03 (d, J = 8.0 Hz, 2H), 7.78 – 7.65 (m, 5H), 7.23 (d, J = 8.4 Hz, 2H), 4.57 – 4.47 (m, 2H), 3.84 – 3.77 (m, 2H), 3.61 (q, J = 7.2 Hz, 2H), 3.11 – 2.99 (m, 4H), 2.86 (s, 3H), 1.26 (t, J = 7.2 Hz, 3H)。
Example 34:
the synthetic route is as follows:
referring to example 2, compound 2-b was replaced with an equivalent of 34-a (i.e., 16-b) and compound 2-c was replaced with an equivalent of 34-b, thus obtaining compound 34 (27 mg, yield 31%) as a yellow solid. LCMS [ M+H] + = 650.1。
1H NMR (400 MHz, CDCl3) δ 8.15 (d, J = 8.0 Hz, 2H), 8.08 (d, J = 8.0 Hz, 2H), 7.82 – 7.67 (m, 5H), 7.27 (s, 2H), 4.57 – 4.46 (m, 2H), 3.75 (s, br, 4H), 3.15 – 2.99 (m, 4H), 2.87 (s, 3H), 2.83 (s, 2H), 2.62 (s, 4H)。
Example 35:
the synthetic route is as follows:
referring to example 2, compound 2-b was replaced with an equivalent of 35-a (i.e., 16-b) and compound 2-c was replaced with an equivalent of 35-b, thus obtaining compound 35 (47 mg, yield 53.4%) as a yellow solid. LCMS [ M+H] + = 608.1。
1H NMR (400 MHz, CDCl3) δ10.23 (s, 1H), 8.15 (d, J = 8.0 Hz, 2H), 8.02 (d, J = 8.0 Hz, 2H), 7.82 – 7.58 (m, 5H), 7.28 – 7.08 (m, 2H), 4.48 (t, J = 5.6 Hz, 2H), 3.16 – 2.97 (m, 4H), 2.85 (s, 3H), 2.78 (t, J = 5.6 Hz, 2H), 2.38 (s, 6H)。
Example 36:
the synthetic route is as follows:
referring to the synthesis of intermediate M-a, methanesulfonyl chloride was replaced with an equivalent amount of acetyl chloride, methyl iodide was replaced with an equivalent amount of trideuterated methyl iodide to give intermediate M-j, and referring again to example 2, compound M-a was replaced with an equivalent amount of M-j, and compound 2-c was replaced with an equivalent amount of 36-c, to give compound 36 as a yellow solid (290 mg, yield 83.8%). LCMS [ M+H] + = 529.1。
1H NMR (400 MHz, DMSO-d6) δ 12.81 (s, 1H), 8.25 (d, J = 8.0 Hz, 2H), 8.06 (d, J = 8.4 Hz, 2H), 7.98 – 7.89 (m, 4H), 7.76 (d, J = 8.0 Hz, 1H), 7.26 (s, 1H), 7.22 (d, J = 8.4 Hz, 1H), 4.34 (q, J = 7.2 Hz, 2H), 3.05 - 2.98 (m, 4H), 1.82 (s, 3H), 1.34 (t, J = 7.2 Hz, 3H)。
Example 37:
the synthetic route is as follows:
referring to the synthesis of intermediate M-a, methanesulfonyl chloride was replaced with an equivalent of 1-methoxyacetyl chloride, methyl iodide was replaced with an equivalent of trideuterated methyl iodide to give intermediate M-k, and referring again to example 2, compound M-a was replaced with an equivalent of M-k, and compound 2-c was replaced with an equivalent of 37-c, to give compound 37 as a yellow solid (33.7. 33.7 mg, yield 58.8%). LCMS [ M+H ] + = 559.1。
1H NMR (400 MHz, DMSO-d6) δ 12.81 (s, 1H), 8.25 (d, J = 8.0 Hz, 2H), 8.07 (d, J = 8.0 Hz, 2H), 7.98 – 7.88 (m, 4H), 7.75 (d, J = 8.0 Hz, 1H), 7.27 (s, 1H), 7.23 (d, J = 8.0 Hz, 1H), 4.34 (q, J = 7.2 Hz, 2H), 3.84 (s, 2H), 3.21 (s, 3H), 3.04 - 3.00 (m, 4H), 1.34 (t, J = 7.2 Hz, 3H)。
Example 38:
the synthetic route is as follows:
referring to the synthesis of intermediate M-a, methanesulfonyl chloride was replaced with an equivalent of ethylsulfonyl chloride, methyl iodide was replaced with an equivalent of trideuterated methyl iodide to give intermediate M-l, and referring again to example 2, compound M-a was replaced with an equivalent of M-l, and compound 2-c was replaced with an equivalent of 38-c, to give compound 38 as a yellow solid (3 mg, yield 12.5%). LCMS [ M+H] + = 579.1。
1H NMR (400 MHz, DMSO-d6) δ 12.82 (s, 1H), 8.25 (d, J = 8.0 Hz, 2H), 8.07 (d, J = 8.4 Hz, 2H), 7.98 – 7.89 (m, 4H), 7.72 (d, J = 8.0 Hz, 1H), 7.34 - 7.32 (m, 2H), 4.34 (q, J = 7.2 Hz, 2H), 3.16 (q, J = 7.6 Hz, 2H), 3.05 - 2.97 (m, 4H), 1.34 (t, J = 7.2 Hz, 3H), 1.22 (t, J = 7.2 Hz, 3H)。
Example 39:
the synthetic route is as follows:
referring to the synthesis of intermediate M-a, methanesulfonyl chloride was replaced with an equivalent of propylsulfonyl chloride, methyl iodide was replaced with an equivalent of trideuterated methyl iodide to give intermediate M-M, and referring again to example 2, compound M-a was replaced with an equivalent of M-M, and compound 2-c was replaced with an equivalent of 38-c, to give compound 39 as a yellow solid (3 mg, yield 12.5%). LCMS [ M+H] + = 593.1。
1H NMR (400 MHz, DMSO-d6) δ 12.82 (s, 1H), 8.25 (d, J = 8.0 Hz, 2H), 8.07 (d, J = 8.4 Hz, 2H), 7.98 – 7.87 (m, 4H), 7.72 (d, J = 8.4 Hz, 1H), 7.34 - 7.32 (m, 2H), 4.34 (q, J = 7.2 Hz, 2H), 3.12 (t, J = 7.6 Hz, 2H), 3.05 - 2.97 (m, 4H), 1.74 - 1.65 (m, 2H), 1.34 (t, J = 7.2 Hz, 3H), 0.97 (t, J = 7.2 Hz, 3H)。
Example 40:
the synthetic route is as follows:
referring to the synthesis of intermediate M-a, the replacement of methanesulfonyl chloride with an equivalent of isobutylsulfonyl chloride and the replacement of iodomethane with an equivalent of trideuterated iodomethane gives intermediate M-n, referring again to example 2,the yellow solid compound 40 (15.2. 15.2 mg, 17.4% yield) was synthesized by substituting the compound M-a with an equivalent of M-n and the compound 2-c with an equivalent of 40-c. LCMS [ M+H ] + = 607.1。
1H NMR (400 MHz, DMSO-d6) δ 12.82 (s, 1H), 8.25 (d, J = 8.4 Hz, 2H), 8.07 (d, J = 8.4 Hz, 2H), 7.98 – 7.89 (m, 4H), 7.72 (d, J = 8.8 Hz, 1H), 7.34 - 7.31 (m, 2H), 4.35 (q, J = 7.2 Hz, 2H), 3.12 (t, J = 7.6 Hz, 2H), 3.05 - 2.97 (m, 6H), 2.15 - 2.08 (m, 1H), 1.35 (t, J = 7.2 Hz, 3H), 1.02 (s, 3H), 1.00 (s, 3H)。
Example 41:
the synthetic route is as follows:
referring to the synthesis of intermediate M-a, the replacement of methanesulfonyl chloride with an equivalent of trifluoromethanesulfonyl chloride and the replacement of iodomethane with an equivalent of trideuterated iodomethane gave intermediate M-o, and referring again to example 2, the replacement of compound M-a with an equivalent of M-o and the replacement of compound 2-c with an equivalent of 41-c gave compound 41 as a yellow solid (31.9. 31.9 mg, yield 41.8%). LCMS [ M+H] + = 619.1。
1H NMR (400 MHz, DMSO-d6) δ 12.85 (s, 1H), 8.25 (d, J = 8.0 Hz, 2H), 8.07 (d, J = 8.4 Hz, 2H), 8.04 – 7.85 (m, 4H), 7.78 (d, J = 8.4 Hz, 1H), 7.43 - 7.38 (m, 2H), 4.34 (q, J = 7.2 Hz, 2H), 3.06 - 3.01 (m, 4H), 1.34 (t, J = 7.2 Hz, 3H)。
Example 42:
the synthetic route is as follows:
referring to the synthesis of intermediate M-a, methanesulfonyl chloride was replaced with an equivalent of cyclopropylsulfonyl chloride, methyl iodide was replaced with an equivalent of trideuterated methyl iodide to obtain intermediate M-p, and referring again to example 2, compound M-a was replaced with an equivalent of M-p, and compound 2-c was replaced with an equivalent of 42-c, to obtain compound 42 as a yellow solid (31.9. 31.9 mg, yield 41.8%). LCMS [ M+H] + = 591.1。
1H NMR (400 MHz, DMSO-d6) δ 12.81 (s, 1H), 8.25 (d, J = 8.0 Hz, 2H), 8.06 (d, J = 8.4 Hz, 2H), 7.97 – 7.89 (m, 4H), 7.73 (d, J = 8.8 Hz, 1H), 7.36 - 7.34 (m, 2H), 4.34 (q, J = 7.2 Hz, 2H), 3.05 - 2.98 (m, 4H), 2.73 - 2.66 (m, 1H), 1.34 (t, J = 7.2 Hz, 3H), 0.99 - 0.95 (m, 2H), 0.86 - 0.82 (m, 2H)。
Example 43:
the synthetic route is as follows:
referring to example 42, compound 42-c was replaced with an equivalent amount of 43-b (the same compound as that of compound 42-b and 43-a), and yellow solid compound 43 was synthesized (72.4. 72.4 mg, yield 60.8%). LCMS [ M+H] + = 676.1。
1 H NMR (400 MHz, CDCl3) δ 10.25 (s, 1H), 8.14 (d, J = 7.6 Hz, 2H), 8.02 (d, J = 7.2 Hz, 2H), 7.72 - 7.65 (m, 5H), 7.27 - 7.24 (m, 2H), 4.51 (t, J = 5.6 Hz, 2H), 3.74 (t, J = 4.0 Hz, 4H), 3.08 - 3.01 (m, 4H), 2.82 (t, J = 5.6 Hz, 2H), 2.60 (t, J = 4.0 Hz, 4H), 2.40 - 2.33 (m, 1H), 1.12 - 1.08 (m, 2H), 0.95 - 0.90 (m, 2H)。
Example 44:
the synthetic route is as follows:
referring to the synthesis of intermediate M-a, methanesulfonyl chloride was replaced with an equivalent amount of 6-sulfonylchlorobenzo [ d ] ]Thiazole, substitution of methyl iodide with equivalent amount of trideuterated methyl iodide to give intermediate M-q, and further reference to example 2, substitution of compound M-a with equivalent amount of M-q and substitution of compound 2-c with equivalent amount of 44-c, yellow solid compound 44 (47.9. 47.9 mg, yield 68.5%) was synthesized. LCMS [ M+H] + = 684.1。
1 H NMR (400 MHz, DMSO-d6) δ 12.81 (s, 1H), 9.64 (s, 1H), 8.57 (s, 1H), 8.28 – 8.15 (m, 3H), 8.06 (d, J = 8.4 Hz, 2H), 8.04 – 7.85 (m, 4H), 7.65 (d, J = 8.0 Hz, 1H), 7.63 – 7.52 (m, 1H), 7.07 (s, 1H), 7.04 – 6.91 (m, 1H), 4.34 (q, J = 7.2 Hz, 2H), 2.95 (s, 4H), 1.34 (t, J = 7.2 Hz, 3H)。
Example 45:
the synthetic route is as follows:
referring to example 44, compound 44-c was replaced with an equivalent amount of 45-b (the same compound as that of compound 44-b and 45-a), and thus, compound 43 (64.2. 64.2 mg, yield 55.8%) was synthesized as a yellow solid. LCMS [ M+H] + = 769.1。
1 H NMR (400 MHz, CDCl3) δ 10.07 (s, 1H), 9.20 (s, 1H), 8.27 (s, 1H), 8.18 (d, J = 8.4 Hz, 1H), 8.14 (d, J = 8.4 Hz, 2H), 8.03 (d, J = 8.0 Hz, 2H), 7.73 (d, J = 8.0 Hz, 2H), 7.69 (d, J = 8.0 Hz, 3H), 7.57 (d, J = 8.4 Hz, 1H), 7.07 (s, 1H), 6.81 (d, J = 8.4 Hz, 1H), 4.50 (t, J = 6.0 Hz, 2H), 3.74 (t, J = 4.8 Hz, 4H), 3.01 (s, 4H), 2.81 (t, J = 6.0 Hz, 2H), 2.60 (t, J = 4.4 Hz, 4H)。
Example 46:
the synthetic route is as follows:
referring to intermediate M-a, methanesulfonyl chloride was replaced with an equivalent of benzenesulfonyl chloride, methyl iodide was replaced with an equivalent of trideuterated methyl iodide, and intermediate M-r was synthesized, and referring to example 2, compound M-a was replaced with an equivalent of M-r, and compound 2-c was replaced with an equivalent of 46-c, and yellow solid compound 46 (60.2 mg, yield 77.9%) was synthesized. LCMS [ M+H] + = 627.1。
1 H NMR (400 MHz, DMSO-d6) δ 12.81 (s, 1H), 8.25 (d, J = 8.0 Hz, 2H), 8.07 (d, J = 8.0 Hz, 2H), 8.02 – 7.85 (m, 4H), 7.71 (t, J = 7.2 Hz, 1H), 7.65 (d, J = 8.4 Hz, 1H), 7.61 - 7.53 (m, 4H), 7.04 (s, 1H), 7.01 – 6.85 (m, 1H), 4.34 (q, J = 7.2 Hz, 2H), 2.96 (s, 4H), 1.34 (t, J = 7.2 Hz, 3H)。
Example 47:
the synthetic route is as follows:
referring to the synthesis of intermediate M-a, methanesulfonyl chloride was replaced with an equivalent amount of p-toluenesulfonyl chloride, methyl iodide was replaced with an equivalent amount of trideuterated methyl iodide to obtain intermediate M-s, and referring again to example 2, compound M-a was replaced with an equivalent amount of M-s, compound 2-c was replaced with an equivalent amount of 47-c to obtain yellow solid compound 47 (52.6 mg, Yield 72.9%). LCMS [ M+H] + = 641.1。
1 H NMR (400 MHz, DMSO-d6) δ 12.81 (s, 1H), 8.25 (d, J = 8.0 Hz, 2H), 8.07 (d, J = 8.4 Hz, 2H), 8.04 – 7.85 (m, 4H), 7.65 (d, J = 8.0 Hz, 1H), 7.44 - 7.38 (m, 4H), 7.06 (s, 1H), 7.01 – 6.85 (m, 1H), 4.34 (q, J = 7.2 Hz, 2H), 2.97 (s, 4H), 2.39 (s, 3H), 1.34 (t, J = 7.2 Hz, 3H)。
Example 48:
the synthetic route is as follows:
referring to the synthesis of intermediate M-a, methanesulfonyl chloride was replaced with an equivalent of p-fluorobenzenesulfonyl chloride, methyl iodide was replaced with an equivalent of trideuterated methyl iodide to give intermediate M-t, and referring again to example 2, compound M-a was replaced with an equivalent of M-t, and compound 2-c was replaced with an equivalent of 48-c to give compound 48 as a yellow solid (47.5 mg, yield 72%). LCMS [ M+H] + = 645.1。
1 H NMR (400 MHz, DMSO-d6) δ 12.81 (s, 1H), 8.25 (d, J = 8.0 Hz, 2H), 8.07 (d, J = 8.4 Hz, 2H), 8.04 – 7.85 (m, 4H), 7.66 (d, J = 8.0 Hz, 1H), 7.62 - 7.58 (m, 2H), 7.44 (t, J = 8.4 Hz, 2H), 7.06 (s, 1H), 7.01 – 6.85 (m, 1H), 4.34 (q, J = 7.2 Hz, 2H), 2.97 (s, 4H), 1.34 (t, J = 7.2 Hz, 3H)。
Example 49:
the synthetic route is as follows:
referring to the synthesis of intermediate M-a, methanesulfonyl chloride was replaced with an equivalent amount of 3-cyano-4-fluorobenzenesulfonyl chloride, methyl iodide was replaced with an equivalent amount of trideuterated methyl iodide to obtain intermediate M-u, and referring again to example 2, compound M-a was replaced with an equivalent amount of M-u, and compound 2-c was replaced with an equivalent amount of 49-c, to obtain compound 49 (47.4 mg, yield 69%) as a yellow solid. LCMS [ M+H] + = 670.1。
1 H NMR (400 MHz, DMSO-d6) δ 12.81 (s, 1H), 8.25 (d, J = 8.0 Hz, 2H), 8.23 – 8.11 (m, 1H), 8.07 (d, J = 8.4 Hz, 2H), 7.99 – 7.89 (m, 4H), 7.83 - 7.78 (m, 1H), 7.72 (t, J = 8.0 Hz, 1H), 7.68 (d, J = 8.0 Hz, 1H), 7.09 (s, 1H), 7.05 – 6.79 (m, 1H), 4.34 (q, J = 7.2 Hz, 2H), 2.98 (s, 4H), 1.34 (t, J = 7.2 Hz, 3H)。
Example 50:
the synthetic route is as follows:
referring to the synthesis of intermediate M-a, methanesulfonyl chloride was replaced with an equivalent of benzylsulfonyl chloride, methyl iodide was replaced with an equivalent of trideuterated methyl iodide to give intermediate M-v, and referring again to example 2, compound M-a was replaced with an equivalent of M-v, and compound 2-c was replaced with an equivalent of 50-c to give compound 50 as a yellow solid (59.2 mg, yield 37.7%). LCMS [ M+H ] + = 641.1。
1 H NMR (400 MHz, DMSO-d6) δ 12.81 (s, 1H), 8.25 (d, J = 8.0 Hz, 2H), 8.07 (d, J = 8.0 Hz, 2H), 7.99 – 7.89 (m, 4H), 7.68 (d, J = 8.4 Hz, 1H), 7.41 -7.36 (m, 5H), 7.25 – 7.13 (m, 4H),, 7.09 (s, 1H), 4.55 (s, 2H), 4.34 (q, J = 7.2 Hz, 2H), 2.98 (s, 4H), 1.34 (t, J = 7.2 Hz, 3H)。
Example 51:
the synthetic route is as follows:
referring to example 1, compound 1-a was replaced with an equivalent amount of 51-a, and thus, a yellow solid compound 51 was synthesized (35 mg, yield 30%). LCMS [ M+H] + = 448.1。
1 H NMR (400 MHz, DMSO-d6) δ 12.79 (s, 1H), 8.11 (d, J = 6.0 Hz, 2H), 7.70 (d, J = 6.0 Hz, 1H), 7.60 (d, J = 6.8 Hz, 2H), 7.32-7.29 (m, 2H), 3.22 (s, 3H), 3.03-2.97 (m, 4H), 2.95 (s, 3H)。
Example 52:
the synthetic route is as follows:
referring to example 1, compound 1-a was replaced with an equivalent amount of 52-a to synthesize yellow solid compound 52 (84 mg, yield 54%). LCMS [ M+H] + = 482.1。
1 H NMR (400 MHz, DMSO-d6) δ 12.98 (s, 1H), 8.49 (s, 1H), 8.38 (d, J = 6.0 Hz, 1H), 7.99 (d, J = 6.0 Hz, 1H), 7.78 (t, J = 6.0 Hz, 1H), 7.71 (d, J = 6.0 Hz, 1H), 7.32 (d, J = 4.4 Hz, 1H), 3.23 (s, 3H), 3.02-2.98 (m, 4H), 2.95 (s, 3H)。
Example 53:
the synthetic route is as follows:
referring to example 1, compound 1-a was replaced with an equivalent of 53-a to synthesize yellow solid compound 53 (70 mg, yield 45%). LCMS [ M+H] + = 432.1。
1 H NMR (400 MHz, DMSO-d6) δ 12.72 (s, 1H), 8.20-8.17 (m, 2H), 7.71 (d, J = 6.0 Hz, 1H), 7.37 (t, J = 6.0 Hz, 2H), 7.32-7.29 (m, 2H), 3.23 (s, 3H), 3.02-2.97 (m, 4H), 2.95 (s, 3H)。
Example 54:
the synthetic route is as follows:
referring to example 19, compound 18 was replaced with an equivalent of 20 to afford compound 54 as a yellow solid (38 mg, 51% yield). LCMS [ M+H] + = 534.1。
1 H NMR (400 MHz, DMSO-d6) δ 12.80 (s, 1H), 8.24 (d, J = 6.4 Hz, 2H), 8.05 (d, J = 6.4 Hz, 2H), 7.92 - 7.89 (m, 4H), 7.73 (d, J = 6.0 Hz, 1H), 7.32 (d, J = 6.4 Hz, 2H), 3.24 (s, 3H), 3.05 - 2.99 (m, 4H), 2.96 (s, 3H)。
Example 55:
the synthetic route is as follows:
referring to example 4, compound 2 was replaced with an equivalent of 54 to synthesize yellow solid compound 55 (20 mg, yield 52.3%)。 LCMS [M+H] + = 532.1。
1 H NMR (400 MHz, DMSO-d6) δ 13.19 (s, 1H), 8.59 (d, J = 6.4 Hz, 1H), 8.31 (d, J = 6.4 Hz, 2H), 8.15 (d, J = 6.4 Hz, 1H), 8.10 (s, 1H), 8.06 (d, J = 6.0 Hz, 2H), 7.97 - 7.91 (m, 4H), 7.87 (d, J = 6.4 Hz, 1H), 7.73 (d, J = 6.8 Hz, 1H), 3.37 (s, 3H), 3.02 (s, 3H)。
Example 56:
the synthetic route is as follows:
referring to example 19, compound 18 was replaced with an equivalent of 21 to afford compound 56 as a yellow solid (17 mg, 35.2% yield). LCMS [ M+H] + = 537.1。
1 H NMR (400 MHz, DMSO-d6) δ 12.79 (s, 1H), 8.24 (d, J = 6.0 Hz, 2H), 8.05 (d, J = 6.4 Hz, 2H), 7.91 (t, J = 5.6 Hz, 4H), 7.73 (d, J = 6.4 Hz, 1H), 7.33 - 7.31 (m, 2H), 3.03 - 2.99 (m, 4H), 2.96 (s, 3H)。
Example 57:
the synthetic route is as follows:
referring to example 19, compound 18 was replaced with 42 equivalents to afford compound 57 as a yellow solid (18.6, mg, 17.8% yield). LCMS [ M+H ] + = 563.1。
1 H NMR (400 MHz, DMSO-d6) δ 12.82 (s, 1H), 8.24 (d, J = 8.4 Hz, 2H), 8.05 (d, J = 8.0 Hz, 2H), 7.93 - 7.90 (m, 4H), 7.73 (d, J = 8.4 Hz, 1H), 7.36 - 7.34 (m, 2H), 3.06 - 2.97 (m, 4H), 2.73 - 2.66 (m, 1H), 1.00 - 0.95 (m, 2H), 0.86 - 0.82 (m, 2H)。
Example 58:
the synthetic route is as follows:
referring to example 19, compound 18 was replaced with an equivalent of 44 to afford compound 58 as a yellow solid (2.8, mg, yield 2.6%). LCMS [ M+H] + = 656.1。
1 H NMR (400 MHz, DMSO-d6) δ 12.83 (s, 1H), 9.64 (s, 1H), 8.58 (s, 1H), 8.24 (d, J = 8.0 Hz, 3H), 8.05 (d, J = 7.6 Hz, 2H), 7.91 (t, J = 7.2 Hz, 3H), 7.64 (d, J = 8.4 Hz, 1H), 7.59 (d, J = 7.6 Hz, 1H), 7.07 (s, 1H), 6.99 (d, J = 8.0 Hz, 1H), 2.95 (s, 4H)。
Effect of COUP inhibitors on proliferation Activity of prostate cancer cells
1. Method of
Prostate cancer cells LNCaP, PC-3, DU-145 were seeded in 96-well plates at a density of 1.5X104/well and incubated overnight at 37℃in 5% CO 2. The next day, the compounds were diluted at a maximum concentration of 100 uM at a 3-fold gradient, added to the cell culture medium at 10 total concentrations for a further treatment of 24 h, and split into 2 total wells.
After 24 h treatment of the cells with the compound, the cell viability was determined according to CellTiter 96 [ b ] AQueous One Solution Cell Proliferation Assay kit (Promega, G3580) as follows: mu.L MTS reagent is added into each hole, the mixture is placed in an incubator for incubation for 1 hour at 37 ℃, and the absorbance is measured by an MD i3x multifunctional enzyme label instrument with the wavelength of 490 and nM.
The effect of compounds on cell proliferation was evaluated as cell viability and IC50 values were calculated using GraphPad prism8.0 software to fit dose-response curves with three parameters. Cell viability= (signal value of sample-signal value of medium control)/(signal value of DMSO control-signal value of medium control) ×100%. Inhibition ratio = (1-cell viability) ×100%.
2. Results
*: IC50 > 10μM; **:10μM ≥ IC50 > 1μM; ***:1μM ≥ IC50 > 0.1μM; ****:0.1μM ≥ IC50
†:30 ≥ Max;††:50 ≥Max > 30;†††:70 ≥Max > 50;††††: Max > 70
Summarizing: the compound provided by the invention has better inhibition activity on the proliferation of prostate cancer cells.
Method for detecting inhibition activity of compound on COUP-TF II based on reporter gene activity detection
1. Method of
1.1 Plasmid cotransfection HEK293T cells and compound treatment
HEK293T cells were seeded at a density of 1X 104/well in 96-well plates one day prior to plasmid transfection. Cell transfection was performed according to the instructions of transfection reagent F. Mu. GENE cube HD (Promega, # E2311). The method mainly comprises the following steps: taking a single well as an example, the plasmids pCR3.1-COUP-TFII and pXP2-NGFIA-Luc were added to 10. Mu.L of Opti-MEM ™ I medium (Gibco, # 11058021) at a ratio of 20ng to 5 ng and mixed well; adding 0.2 mu L of Fmu gENE cube HD, uniformly mixing, and standing at 20 ℃ for 5 min; this 10. Mu.L mixture was then added to the cell well containing 100. Mu.L of culture medium. After cell co-transfection 6 h, the compounds were diluted in a gradient at 100 uM at maximum concentration at half log dilution, 10 total concentrations were added to cell culture broth for treatment 24 h total of 2 multiplex wells.
1.2 One-Glo Luciferase assay
Cells were treated with the compound 24 h and examined according to ONE-Glo Luciferase Assay System (Promega, # E6120) instructions. The method mainly comprises the following steps: 50 mu L of culture solution is sucked and removed from each hole, 50 mu L of ONE-Glo Luciferase reagent is added, and the mixture is oscillated for 10 min at 20 ℃; mu.L of the cleavage reaction solution was transferred to a white opaque optiPlate-96 well plate, and the luminescence signal value (Firefly-Luc) of Firefly luciferase (Firefly luciferase) was detected by an MD i3x multifunctional microplate reader. EC50 values were calculated using the Firefly-Luc signal values as inhibitory activity of the compounds on COUP-TF II, normalized to the ratio of solvent DMSO groups, and dose-response curves fitted with three parameters using GraphPad prism8.0 software. And the inhibition ratio was calculated as the following formula = (Luc of Luc/DMSO group of 1-compound treated samples) ×100%. VCT-8 was used as a positive control compound (WO 2019/222134).
2. Results
Experimental data are shown in the following table.
*:20μM ≥ EC50 > 5μM; **:5μM ≥ EC50 > 1μM; ***:1μM ≥ EC50 > 0.1μM;
****:0.1μM ≥ EC50
†:20 ≥ Max;††:40 ≥ Max > 20;†††:70 ≥Max > 40;††††: Max > 70
Summarizing: the compound provided by the invention has better inhibition activity on COUP-TFII.
Method for detecting inhibition activity of compound on NRF2 based on reporter gene activity detection
1. Method of
1.1 Plasmid cotransfection HEK293T cells and compound treatment
pGL4.37[ luc2P/ARE ] (Promega, # E3641) and pRL-TK (Promega, # E2241) plasmids were purchased from Promega; the DH 5. Alpha. E.coli was transformed with the plasmid by CaCl2 method, and after further culture amplification, the corresponding plasmid DNA was obtained by purification using plasmid extraction kit (TIANGEN, #D107). HEK293T cells were seeded at a density of 1X 104/well in 96-well plates one day prior to plasmid transfection. Cell transfection was performed according to the instructions of transfection reagent F. Mu. GENE cube HD (Promega, # E2311). The method mainly comprises the following steps: taking a single well as an example, plasmids pGL4.37[ luc2P/ARE ] and pRL-TK were added to 10. Mu.L of Opti-MEM ™ I medium (Gibco, # 11058021) at a ratio of 80ng to 8 ng and mixed well; adding 0.2 mu L of Fmu gENE cube HD, uniformly mixing, and standing at 20 ℃ for 5 min; this 10. Mu.L mixture was then added to the cell well containing 100. Mu.L of culture medium. After cell co-transfection 6 h, the compounds were diluted in a gradient at 100 uM at maximum concentration at half log dilution, 10 total concentrations were added to cell culture broth for treatment 24 h total of 2 multiplex wells.
1.2 Dual-Glo Luciferase assay
Cells were treated with the compound 24 h and tested according to the Dual-Glo Luciferase Assay System (Promega, # E2940) instructions. The method mainly comprises the following steps: 50 mu L of culture solution is sucked and removed from each well, 50 mu L of Dual-Glo Luciferase reagent is added, and the mixture is oscillated for 10 min at 20 ℃; taking 80 mu L of the cleavage reaction solution to a white opaque optiPlate-96 well plate, and detecting a luminescence signal value (Firefly-Luc) of Firefly luciferase (Firefly luciferase) by using an MD i3x multifunctional enzyme-labeled instrument; then 40 mu L of Dual-Glo cube Stop & Glo cube reagent is added, and the mixture is oscillated for 10 min at 20 ℃; the luminescence signal value (Renilla-Luc) of Renilla luciferase (Renilla luciferase) was detected by an MD i3x multifunctional microplate reader. EC50 values were calculated using GraphPad prism8.0 software to fit dose-response curves with three parameters, with the ratio of Firefly-Luc/Renilla-Luc as the inhibitory activity of the compound on NRF2, and normalized to the ratio of solvent DMSO group. And the inhibition ratio (inhibition ratio) was calculated as follows, inhibition = (ratio of 1-compound treated sample of Firefly-Luc/Renila-Luc/ratio of DMSO group of Firefly-Luc/Renila-Luc) ×100%.
2. Results
Experimental data are given in the following table:
*: EC50 > 20μM; **:20μM ≥ EC50 > 10μM; ***:10μM ≥ EC50 > 1μM;****:1μM ≥ EC50;
†:20 ≥ Max;††:40 ≥ Max > 20;†††:70 ≥Max > 40;††††: Max > 70
summarizing: the compound provided by the invention also has better inhibition activity on NRF 2.
Pharmacokinetic evaluation
In mice, the bioavailability and pharmacokinetic behavior of the compounds were evaluated. 6 male ICR mice of similar body weight were selected, of which 3 were given 10 mg/kg by single gavage and 3 were given intravenously at a single dose of 5 mg/kg. Blood samples were taken at time points of 5 minutes (intravenous), 15 minutes, 30 minutes, 1 hour, 2 hours, 4 hours and 7 hours post-dose, plasma samples were analyzed for concentration by LC-MS/MS and the pharmacokinetic parameters of the compounds were analyzed using PKSolver free tools and non-compartmental model (NCA) software.
Experimental protocol:
experimental animals: each compound test group consisted of 6 healthy male ICR mice, 18-25 g, purchased from Charles River, randomly divided into 2 groups of 3.
Preparation: weighing a certain amount of compound, adding into 2% DMSO+15% Solutol+83% physiological saline, and preparing into clear solution.
Dosage is as follows: ICR mice were fasted overnight and the compounds were administered at either a gastric lavage dose of 10 mg/kg or a dose of 5 mg/kg intravenously. The administration volumes for intragastric and intravenous administration were 10 mL/kg and 5 mL/kg, respectively. Unified feeding is performed 2 hours after administration.
Sample collection: about 30 μl of blood was collected through the great saphenous vein 5 minutes (intravenous), 15 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, and 7 hours after administration. Blood is put into a container containing K 2 In commercial test tubes of EDTA, thenBlood samples were centrifuged at 4600 rpm at 4 ℃ for 5 minutes to obtain plasma samples, and then all plasma samples were flash frozen on dry ice and kept at-70 ℃ until LC-MS/MS analysis was performed.
Sample preparation: mu.L of plasma sample was aspirated, precipitated with 50 nmol/L of alpha-naphthaleneflavone (internal standard) in methanol, the mixture was thoroughly mixed and centrifuged at 14000 rpm for 5 minutes at 4℃and 75. Mu.L of supernatant was then mixed with 75. Mu.L of methanol for LC-MS/MS analysis.
The pharmacokinetic parameter results are shown in table 1.
TABLE 1
Conclusion: the compound has better absorption in mice, proper elimination, high exposure and higher bioavailability, and can be used for further research.
The applicant states that the present invention is illustrated by the above examples for the benzomulti-ring thiazoline amides of the present invention and the use thereof, but the present invention is not limited to the above examples, i.e., it is not meant that the present invention must be practiced by relying on the above examples. It should be apparent to those skilled in the art that any modification of the present invention, equivalent substitution of raw materials for the product of the present invention, addition of auxiliary components, selection of specific modes, etc., falls within the scope of the present invention and the scope of disclosure.
The preferred embodiments of the present invention have been described in detail above, but the present invention is not limited to the specific details of the above embodiments, and various simple modifications can be made to the technical solution of the present invention within the scope of the technical concept of the present invention, and all the simple modifications belong to the protection scope of the present invention.
In addition, the specific features described in the above embodiments may be combined in any suitable manner, and in order to avoid unnecessary repetition, various possible combinations are not described further.
Claims (10)
1. The benzo-multi-ring thiazoline amide compound is characterized by having a structure shown in the following formula I:
wherein the ring A is selected from any one of C5-C8 cyclodiene, C4-C8 epoxydiene or C6-C10 aromatic ring;
the B ring is selected from any one of substituted or unsubstituted C6-C12 aryl, substituted or unsubstituted C4-C12 nitrogen-containing heteroaryl and substituted or unsubstituted C4-C12 oxygen-containing heteroaryl;
R 1 、R 2 independently selected from any one of hydrogen, substituted or unsubstituted C1-C10 straight or branched chain alkyl, substituted or unsubstituted C7-C10 arylalkyl, substituted acyl and substituted sulfonyl.
2. The benzomulti-ring thiazoline amide of claim 1 wherein the substituents of said C6-C12 aryl, C4-C12 nitrogen containing heteroaryl, or C4-C12 oxygen containing heteroaryl are independently selected from hydroxy, halogen, unsubstituted, or R a Substituted C1-C10 straight-chain or branched alkyl, unsubstituted or R a Substituted C1-C10 alkoxy, unsubstituted or R b Substituted C6-C12 aryl, unsubstituted or R b Any one of substituted C5-C12 nitrogen-containing heteroaryl;
the R is a Selected from halogen or deuterium, said R b Selected from the group consisting of C1-C10 straight or branched alkyl, C1-C10 haloalkyl, C1-C10 alkoxy,or-COOR c Any one of the above, R c Any one selected from hydrogen, C1-C10 straight-chain alkyl or branched-chain alkyl, C1-C10 alkoxy, C1-C10 alkylamino or C1-C10 heterocyclic group;
3. The benzomulti-ring thiazoline amide compound of claim 1, wherein the substituent of the straight-chain alkyl or branched-chain alkyl is selected from halogen, hydrogen or deuterium;
preferably, the acyl, sulfonyl, C1-C10 straight or branched alkyl, C7-C10 arylalkyl substituents are independently selected from C1-C10 straight or branched alkyl, C1-C10 alkoxy, C1-C10 haloalkyl, C3-C10 cycloalkyl, unsubstituted or R d Substituted C6-C12 aryl, unsubstituted or R d Any of the substituted C5-C12 heteroaryl groups; the R is d Any one of halogen, cyano, C1-C10 straight-chain alkyl or branched-chain alkyl.
4. A benzomulti-ring thiazoline amide according to any of claims 1-3 wherein the a ring is selected from a benzene ring orX is selected from-CH 2 -or-O-;
n is selected from 0, 1 or 2, and n is 0, which indicates that the group is absent, and X is directly connected with the other end;
5. The benzomulti-ring thiazoline amide compound according to any of claims 1 to 4, wherein said B ring is selected from the group consisting ofAny one of them;
wherein Y is selected from-ch=or-n=, Z' is selected from-O-or-NH-;
R 3 、R 4 independently selected from the group consisting of-H, -OH, -OMe, -OCD 3 、-F、-Cl、-CF 3 、Any one of them;
z is selected from-ch=or-n=;
6. The benzomulti-ring thiazoline amide compound according to any of claims 1 to 5, wherein said R 1 、R 2 Independently selected from-H, -Me, -CD 3 、-Et、-i-Pr、-Bn、Any one of them;
wherein ,Rg Selected from-Me or MeOCH 2 -,R h Selected from-Me, -Et, -n-Pr, -i-Bu, -CF 3 、-Bn、Or->Any one of them; r is R i Any one selected from-H, -Me, -F or-CN;
preferably, the benzo-polycyclic thiazoline amide compound is selected from any one of the following formulas 1 to 58:
7. a stereoisomer of a benzopolycyclothiazoline amide compound according to any one of claims 1 to 6, a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising the same;
preferably, the pharmaceutical composition further comprises pharmaceutically acceptable pharmaceutical excipients.
8. Use of a benzopolycyclothiazoline amide compound according to any one of claims 1-6 or a stereoisomer of a benzopolycyclothiazoline amide compound according to claim 7, a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the same, for the manufacture of a medicament for the treatment and/or prevention of a disease associated with excessive activity of COUP-TFII or overexpression of COUP-TFII.
9. The use according to claim 8, wherein the disease associated with excessive activity of COUP-TFII or overexpression of COUP-TFII comprises prostate cancer.
10. Use of a benzopolycyclothiazoline amide compound according to any one of claims 1-6 or a stereoisomer of a benzopolycyclothiazoline amide compound according to claim 7, a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the same, for the manufacture of a medicament for the treatment and/or prevention of a disease associated with excessive NRF2 activity or with overexpression of NRF 2.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310294139.0A CN116003397B (en) | 2023-03-24 | 2023-03-24 | Benzo-polycyclic thiazoline amide compound and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310294139.0A CN116003397B (en) | 2023-03-24 | 2023-03-24 | Benzo-polycyclic thiazoline amide compound and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN116003397A true CN116003397A (en) | 2023-04-25 |
CN116003397B CN116003397B (en) | 2023-06-16 |
Family
ID=86030207
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310294139.0A Active CN116003397B (en) | 2023-03-24 | 2023-03-24 | Benzo-polycyclic thiazoline amide compound and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116003397B (en) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011017519A2 (en) * | 2009-08-05 | 2011-02-10 | The Johns Hopkins University | Inhibitors of methionine aminopeptidases and methods of treating disorders |
CA2849702A1 (en) * | 2011-09-23 | 2013-03-28 | Yuhan Corporation | Phenylimide-containing benzothiazole derivative or its salt and pharmaceutical composition comprising the same |
CN107033100A (en) * | 2017-05-24 | 2017-08-11 | 济南大学 | A kind of benzothiazole derivant, preparation method and its medical usage |
WO2018031707A1 (en) * | 2016-08-10 | 2018-02-15 | Biohaven Pharmaceutical Holding Company Ltd. | Acyl benzo[d]thiazol-2-amine and their methods of use |
WO2019222134A1 (en) * | 2018-05-14 | 2019-11-21 | Baylor College Of Medicine | Coup-tfii receptor inhibitors and methods using same |
CN112930347A (en) * | 2018-08-20 | 2021-06-08 | 詹森药业有限公司 | Inhibitors of KEAP1-Nrf2 protein-protein interactions |
-
2023
- 2023-03-24 CN CN202310294139.0A patent/CN116003397B/en active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011017519A2 (en) * | 2009-08-05 | 2011-02-10 | The Johns Hopkins University | Inhibitors of methionine aminopeptidases and methods of treating disorders |
CA2849702A1 (en) * | 2011-09-23 | 2013-03-28 | Yuhan Corporation | Phenylimide-containing benzothiazole derivative or its salt and pharmaceutical composition comprising the same |
WO2018031707A1 (en) * | 2016-08-10 | 2018-02-15 | Biohaven Pharmaceutical Holding Company Ltd. | Acyl benzo[d]thiazol-2-amine and their methods of use |
CN107033100A (en) * | 2017-05-24 | 2017-08-11 | 济南大学 | A kind of benzothiazole derivant, preparation method and its medical usage |
WO2019222134A1 (en) * | 2018-05-14 | 2019-11-21 | Baylor College Of Medicine | Coup-tfii receptor inhibitors and methods using same |
CN112930347A (en) * | 2018-08-20 | 2021-06-08 | 詹森药业有限公司 | Inhibitors of KEAP1-Nrf2 protein-protein interactions |
Non-Patent Citations (1)
Title |
---|
JINHONG REN ET AL.: "Exploring small molecules with pan-genotypic inhibitory activities against hepatitis C virus NS3/4A serine protease", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 29, pages 2349, XP085758996, DOI: 10.1016/j.bmcl.2019.06.009 * |
Also Published As
Publication number | Publication date |
---|---|
CN116003397B (en) | 2023-06-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3070089B1 (en) | Aminomethyl tryptanthrin derivative, preparation method and application thereof | |
CN108250122B (en) | Sulfonamide-aryl amide compounds and pharmaceutical use thereof for treating hepatitis B | |
EA022813B1 (en) | METHOD FOR PURIFYING METHYL{4,6-DIAMINO-2-[1-(2-FLUOROBENZYL)-1H-PYRAZOLO[3,4-b]PYRIDINO-3-YL]PYRIMIDINO-5-YL}METHYL CARBAMATE AND A DERIVATIVE THEREOF AS SULFINYLDIMETHANE | |
CN110099900B (en) | Hedgehog pathway inhibitors against Smoothened mutants | |
JP2020097526A (en) | Heterocyclic compound | |
KR102530597B1 (en) | Compounds that induces anti-aging gene klotho and use thereof | |
AU2005217174A1 (en) | Hydrazide type compounds and the use thereof in pharmaceutical compositions for the treatment of cardiovascular diseases | |
CN114409680B (en) | PPAR agonists and uses thereof | |
WO2012037351A1 (en) | Compounds | |
CN116262736A (en) | Novel oxo-pyridine compound and preparation method and application thereof | |
CN106905319A (en) | The preparation method of substitution benzene sulfonyl kuh-seng butane or its hydrochloride | |
CN116003397B (en) | Benzo-polycyclic thiazoline amide compound and application thereof | |
US20080009481A1 (en) | Process For Making Form I Of Olanzapine | |
CN108752412B (en) | Boswellic acid derivatives and their use | |
CN114195776B (en) | Preparation and application of novel FXR small molecule agonist | |
CN117479934A (en) | HIPK2 inhibitors for the treatment of renal fibrosis | |
CN114890997A (en) | Preparation process of anticholinergic drug tiaogelium bromide | |
WO2022063128A1 (en) | Aromatic ring or arylheterocyclic pyridone compound, pharmaceutical compositions, and use thereof | |
CN116199682A (en) | Phenyl thiazolyl benzamide compound and application thereof | |
US8536342B2 (en) | Process for producing thiabenzoazulene-propionic acid derivative | |
BE897208A (en) | CARBOSTYRYLE COMPOUNDS | |
CN112209896A (en) | Thiazolidinedione derivatives and pharmaceutical compositions containing the same | |
ES2297415T3 (en) | INTERMEDIATE COMPOUND THAT IS USED FOR THE PREPARATION OF PIOGLITAZONA. | |
PT1648444E (en) | Indol-7 sulfonamide derivatives, their preparation and their use 5-ht-6 as modulators | |
CN115322208B (en) | 2-aminothiazole derivative and preparation method and medical application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |